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Abstract 
Perturbations in coagulation function are common following trauma and are independently 
associated with poor clinical outcomes. Trauma induced coagulopathy (TIC) was 
traditionally considered an iatrogenic process, attributed to the loss, dilution or dysfunction 
of coagulation proteases. It is now recognised that an acute endogenous coagulation 
dysfunction develops prior to medical intervention in response to a combination of tissue 
injury and hypoperfusion. This acute traumatic coagulopathy (ATC) is still defined clinically 
using traditional assays of coagulation function as a 20% increase in international 
normalised ratio (INR). Efforts have been made to characterise ATC using viscoelastic 
point of care testing; however there is no current universally accepted viscoelastic 
definition. 
 
The pathogenesis of ATC remains poorly understood. Activation of the protein C pathway, 
fibrinolysis, platelet dysfunction and endothelial glycocalyx shedding are all hypothesised 
to play a role in development. However the exact contributions are still unknown and this 
current knowledge gap is impeding the development of effective and tailored resuscitation 
strategies for this subset of patients.  
 
Pre-clinical animal research is a necessary adjunct for improving the understanding and 
management of ATC. Despite considerable interest in developing animal models of ATC 
there are few clinically relevant models that reflect the contemporary understanding of the 
condition. The development of a well-designed animal model of trauma may improve 
mechanistic understanding of ATC and facilitate the development of targeted treatment 
strategies.   
 
This thesis describes an ovine model of complex trauma and haemorrhage that 
demonstrates coagulation changes using both traditional plasma based assays and point 
of care viscoelastic assays that are consistent with current definitions of ATC. The degree 
of coagulopathy was correlated with the degree of shock as quantified by arterial lactate.  
Coagulopathy was also associated with activation of the protein C pathway and shedding 
of the endothelial glycocalyx. Fibrinolysis did not make a significant contribution to the 
coagulopathy observed and there was no evidence of altered platelet function in this 
model.  
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CHAPTER 1: INTRODUCTION 
 
Trauma remains a leading cause of death and disability worldwide, with approximately 
10% of all deaths occurring due to traumatic injury (1). It predominately affects individuals 
younger than 44 years, with an average of 36 life years lost per trauma death (2, 3).  
However trauma has a wider impact than mortality statistics alone can illustrate. For every 
trauma fatality are two survivors who sustain serious or permanent disability, with over 1.8 
billion disability adjusted life years lost annually as a result of traumatic injury (4). Trauma 
therefore has a significant financial impact on society as a consequence of healthcare 
costs and lost productivity, as well as having far reaching personal and emotional effects 
on the individual. 
 
The causative mechanisms of trauma can be divided into blunt and penetrating injuries (5). 
Regardless of the initiating mechanism the temporal distribution and cause of mortality in 
trauma patients remains similar. Between one third and two thirds of trauma deaths occur 
prior to hospital admission and generally result from catastrophic head injury or major 
vessel disruption that is unresponsive to medical intervention and difficult to prevent (5-7).  
Of those trauma patients that survive until arrival to hospital the vast majority (up to 80%) 
will die, primarily during the first 48 hours of admission (3, 8). Despite advances in 
resuscitation, surgical management and critical care, uncontrollable haemorrhage remains 
the leading cause of preventable death during this period (3). 
 
Haemostasis is precipitated by damage to the vascular endothelium, which triggers reflex 
local vasoconstriction and platelet activation in an attempt to minimise haemorrhage 
volume (9). Platelets adhere to the exposed sub-endothelial matrix via a collagen receptor 
and glycoprotein Ib which facilitates binding of von Willebrand factor (10). Adhesion 
triggers platelet activation resulting in changes in the cytoskeleton shape and the secretion 
of agonists such as adenosine diphosphate (ADP), thromboxane A2, adrenaline and 
serotonin to recruit additional platelets (10, 11). The rapid development of this platelet plug 
represents primary haemostasis and is effective in sealing small endothelial lesions in 
isolation. However platelet activation also triggers a cascade of pro-coagulant enzymes 
that results in the formation of a fibrin mesh to stabilise and support the platelet plug, a 
process known as secondary haemostasis. 
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The cascade model of coagulation depicts secondary haemostasis as two separate 
pathways triggered by different stimuli that ultimately result in the formation of fibrin: the 
contact activation (or intrinsic) pathway and the tissue factor (or extrinsic) pathway (figure 
1) (12, 13). The cascade model accurately reflects the identity, function and interactions of 
the individual proteases involved in secondary haemostasis (12, 13). However it fails to 
take into account the contribution of the endothelium and other circulating cells to the 
coagulation process, and is therefore unable to fully explain many clinical bleeding 
syndromes. This has led to the proposal of the cell based model of haemostasis to better 
reflect the process of coagulation in vivo (14). The cell based model consists of 3 phases: 
initiation, amplification and propagation (figure 2). These phases are isolated to specific 
cell surfaces and suggest that the intrinsic and extrinsic pathways of coagulation are not 
redundant systems, but rather operate in parallel using different cell surfaces (14). 
 
 
             Intrinsic Pathway       Extrinsic Pathway 
                              Factor XII                                              
                                 HMK 
                                  PK 
 
                Factor XI              Factor XIa 
 
 
                                Factor IX                Factor IXa                  Factor VIIa       
                                                              Factor VIIIa               Tissue factor 
                 PL, Ca
2+
                     PL, Ca
2+ 
 
 
                                                 Factor X                 Factor Xa                   Factor X 
                                                                                Factor Va 
          PL, Ca
2+
 
                                                      
                                                                        
                                                            Prothrombin                 Thrombin 
 
 
        Fibrinogen                 Fibrin 
   
 
Figure 1. The cascade model of coagulation. Adapted from Hoffman and Monroe 2001 (14) 
Common Pathway 
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Figure 2. The cell based model of coagulation. [A] Initiation phase, [B] Amplification phase,  
[C] Propagation phase. Adapted from Hoffman and Monroe 2001 (14) 
 
Normal pro-coagulant function is balanced by a number of endogenous anti-coagulant 
mechanisms that aim to restrict thrombin formation to the site of injury, avoid uncontrolled 
clotting of the entire vascular tree and inhibit local vessel thrombosis to maintain blood flow 
during periods of reduced perfusion (15-17). Intact endothelium prevents platelet adhesion 
to the thrombogenic subendothelial extracellular matrix and expresses heparin like 
molecules that activate anti-thrombins, inhibiting thrombin and several serine proteases 
including factors IXa, Xa, Xia and XIIa (15). The endothelium also expresses 
thrombomodulin (TM) which activates protein C and S to proteolytically inactivate factors 
Va and VIIIa (16), and produces tissue factor pathway inhibitor (TFPI) which prevents the 
ongoing  tissue factor-factor VII interactions that initiate the extrinsic pathway (18).   
 
Patients experiencing severe trauma often demonstrate impaired coagulation function, 
which complicates efforts to achieve effective haemostasis, increases transfusion 
requirements and contributes to higher mortality rates (19, 20). This trauma induced 
coagulopathy (TIC) has traditionally been attributed to the loss, dilution and dysfunction of 
coagulation proteases in response to fluid resuscitation, hypothermia and acidosis (20, 
21). However it is now recognised that a mechanistically distinct acute traumatic 
coagulopathy (ATC) develops in the hyper-acute post trauma period independent of these 
factors (22, 23). The existence of this early coagulopathy has since been confirmed in a 
number of studies performed by independent research groups (22-26) with a strong 
association between coagulopathy and mortality reported in all studies (table 1).  
 
[A]           [B]         [C] 
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Table 1.  The presence of an early endogenous coagulopathy has been confirmed by a number of 
independent research groups.  In all studies the presence of coagulopathy was associated with a 
higher mortality rate.   
Authors Number of 
patients 
% with ATC Mortality with 
ATC 
Mortality 
without ATC 
Brohi et al (22) 1,088 24.4% 46.0% 10.9% 
MacLeod et al(23) 7,638 28.0% 19.3% 6.3% 
Maegele et al(24) 8724 34.2% 28.0% 8.4% 
Niles et al (25) 347 38.0% 24.0% 7.0% 
Hess et al (26) 23,506 24.3% 26.4% 4.2% 
 
The identification of ATC was originally based upon the traditional transfusion triggers 
recommended by massive transfusion guidelines (27, 28), namely a 50% prolongation of 
prothrombin time (PT), activated partial thromboplastin time (aPTT) or international 
normalised ratio (INR) (22, 23). However subsequent epidemiological work has shown a 
20% increase in INR to be the clinically significant threshold for mortality and blood 
product requirements in trauma (29). More recently efforts have been made to 
characterise ATC using both thromoelastometery (ROTEM) or thromboelastography 
(TEG), reflecting the increasing use of viscoelastic point of care assays in the trauma 
setting (30-35). However there remains no universally accepted viscoelastic definition of 
ATC (36). 
 
ATC appears to develop in response to a combination of tissue injury and systemic 
hypoperfusion (29, 37) and may simply represent the over-zealous activation of normal 
anti-coagulant processes. However the exact pathophysiological mechanisms underlying 
its development remain unclear. It has been suggested that activation of the protein C 
pathway may play a central role, as clinical studies demonstrate an association between 
protein C reduction, coagulopathy and mortality (37-39). The primary theory is that 
pathological activation of protein C results in systemic anticoagulation and hyperfibrinolysis 
via the inactivation of factors Va, VIIIa and plasminogen activator inhibitor-1 (PAI-1) (37, 
38, 40). However the circulating concentration of PAI-1 is roughly ten times that of protein 
C, raising doubts about the ability of activated protein C (aPC) to deplete PAI-1 levels to 
the extent required to accelerate fibrinolysis (41). This has led to suggestions that ATC is a 
fibrinolytic form of disseminated intravascular coagulation (DIC) driven by increased tissue 
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plasminogen activator (tPA) release from the site of injury (21, 42-44). There is also 
emerging evidence to implicate platelet dysfunction and endothelial glycocalyx degradation 
in the development of ATC (45-48), although the exact contributions of these factors 
remains unclear. 
 
Coagulation is also an integral component of the innate immune system, with coagulation 
dysfunction triggering a systemic inflammatory response that is further compounded by 
immunologic responses to blood product transfusion and fluid resuscitation (49, 50).  
Haemostatic resuscitation using combinations of red blood cells, plasma, platelets, 
cryoprecipitate and fibrinogen remains the core therapeutic approach to severe trauma 
(51, 52), and has been combined with adjuncts such as prothrombin complex, recombinant 
activated factor VII and tranexamic acid (TXA)  to further improve haemorrhage control 
(53).This may improve short term mortality rates (52); however the effect on the 
subsequent pro-coagulant state still needs to be quantified. TXA has also been shown to 
impede neutrophil adhesion pathways via the inhibition of plasmin (54, 55). This may 
further alter the immune response in a patient population susceptible to sepsis and 
influence the medium-long term complication rate. Targeted treatment strategies are 
required to further improve outcomes for patients with ATC; however the development of 
these is currently restricted by the limited mechanistic understanding of the condition.   
 
Pre-clinical animal research has become an attractive option for investigating the 
pathogenesis and management of ATC. Human research in the trauma setting can be 
problematic, as the dynamic nature of traumatic injury creates difficulties in the recruitment 
of patients to randomized controlled trials and increases the risk of bias and confounders 
in both prospective and retrospective studies (56, 57). Animal models provide an 
alternative option as they facilitate the controlled and systematic evaluation of isolated 
insults in vivo, which may enhance mechanistic understanding and identify novel 
therapeutic targets. However animals are genetically distinct from humans, and 
demonstrate differences in coagulation assay parameters, coagulation factor 
concentrations and platelet function that may alter the susceptibility to ATC (58-62). For an 
animal model to be clinically relevant there needs to be more similarities than differences 
between the human coagulation system and that of the chosen animal species. 
 
There are a number of published animal models that have attempted to characterise 
changes in coagulation function in response to trauma and haemorrhage (63, 64).  
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However there remains no consensus as to the species or type of traumatic insult that 
most closely replicates the human condition. Rodents have consistently demonstrated the 
ability to achieve clinical definitions of ATC in response to trauma and haemorrhage (29, 
40, 65), however they are limited by animal size and recognized differences in coagulation 
function (58). Pigs are the only large animal species that has been used for evaluating 
ATC, which would appear appropriate given the established physiological similarities 
between pigs and humans (66). However comparative studies of coagulation function have 
shown pigs to be relatively hypercoagulable compared to humans, with protein C levels 
only 36% of human values (58, 60). Given the hypothesized role of protein C in the 
development of ATC it is possible that this fundamental difference may impede the ability 
to successfully model ATC in pigs. The only published porcine model to develop 
coagulation changes consistent with clinical definitions of ATC reports a 25% mortality rate 
in the trauma group (67). This may reflect the severity of injury required to produce ATC in 
this species and raises concerns over the ethical acceptability of this model. The 
predisposition for porcine models may therefore be limiting information about ATC that 
could be obtained from alternative large animal species. 
 
Sheep have been widely used in biomedical research to model a number of human 
pathologies including asthma (68, 69), osteoporosis (70), sepsis (71)  and acute lung injury 
(ALI) (72-74), as they also share many physiological similarities with humans (75-77). 
Comparative studies of human, porcine, rodent, canine and ovine coagulation function 
using routine coagulation tests, rotational thromboelastometry (ROTEM) and clotting factor 
assays also suggest that the human coagulation system demonstrates the greatest 
similarity with that of sheep (58, 59). However there are no current published ovine models 
of ATC. The development of an ovine model of ATC may therefore improve understanding 
of pathophysiology and better inform subsequent human studies.    
 
The primary aims of this thesis were three fold. The first was to undertake a systematic 
review of the literature to identify and evaluate existing animal models of ATC, to better 
inform the design of an alternative large animal model. The second was to develop an 
ovine model of trauma and haemorrhage that demonstrated coagulation changes 
consistent with ATC as defined by INR, aPTT and ROTEM. The third was to evaluate the 
relationships between coagulopathy, the protein C pathway, endothelial glycocalyx, 
platelet function and fibrinolysis within the ovine model to better inform future mechanistic 
studies.   
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CHAPTER 2: AN OVERVIEW OF ACUTE TRAUMATIC COAGULOPATHY 
 
2.1 Background of Acute Traumatic Coagulopathy 
 
Coagulopathy in trauma has classically been considered an iatrogenic process developing 
late after injury in response to haemodilution, acidosis and hypothermia (20). In 2003 two 
separate retrospective clinical studies described an endogenous coagulopathy present at 
hospital admission that had developed in the absence of these physiological 
derangements (22, 23). The existence of this acute traumatic coagulopathy (ATC) has 
since been confirmed in multiple publications from independent research groups and has 
changed our comprehension of coagulopathy in trauma (24-26, 29, 30, 32, 39). It is now 
understood that haemostatic equilibrium is disrupted early post trauma by an endogenous 
dysfunction which is further aggravated by medical interventions promoting the 
development of haemodilution, acidosis and hypothermia (figure 3). 
 
 
 
 
Figure 3. ATC is an endogenous coagulation dysfunction developing in response to tissue injury 
and haemorrhagic shock.  Acidosis, hypothermia and haemodilution simply exacerbate this 
underlying dysfunction, signalling progression to TIC. 
 
The reported incidence of ATC at hospital admission varies from 24-41% depending on 
the diagnostic criteria that is used (table 2) (22-25, 29, 32, 39). However in all studies it is 
associated with a negative impact on patient outcomes. ATC has been independently 
associated with higher transfusion requirements, increased incidence of post injury multi-
organ failure, longer critical care unit stays and a four-fold increase in the risk of mortality 
(22-25, 29) .The inability to control bleeding is the biggest factor contributing to mortality 
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and morbidity in patients with ATC (78). However the presence of ATC is also a strong 
predictor of venous thromboembolism which can further complicate the clinical course (79) 
and knowing when to instigate thromboprophylaxis is difficult in patients presenting with 
coagulopathy. 
 
Table 2. Various definitions of ATC have been proposed in the literature. ATC is associated with a 
negative impact on patient outcomes regardless of the definition used.   
Authors Number Definition % with ATC Mortality 
with ATC 
Mortality 
without 
ATC 
Brohi et al (22) 1,088 PT>18s or aPTT>60s 
or INR>1.5 
24.4% 46.0% 10.9% 
MacLeod et 
al(23) 
7,638 PT>14s or aPTT>34s 28.0% 19.3% 6.3% 
Maegele et 
al(24) 
8724 PT <70% or platelets 
<100x109 
34.2% 28.0% 8.4% 
Niles et al (25) 347 INR>1.5 38.0% 24.0% 7.0% 
Frith et al (29) 3,646 INR>1.2 36.2% 22.7% 7.0% 
Davenport et 
al (32) 
300 ROTEM A5≤35mm 18.0% 23.4% 6.2% 
Cohen et al 
(39) 
1,245 INR>1.3 or aPTT>35s 41.6% by INR 
20.5% by aPTT 
32.6% 12.5% 
PT = prothrombin time, aPTT = activated partial thromboplastin time, INR = international normalised ratio, 
ROTEM A5 = clot amplitude at 5 minutes using rotational thromboelastometry. 
 
The recognition of ATC has driven changes in the clinical management of traumatic injury.  
Resuscitation practices in trauma have shifted away from crystalloid based regimens 
towards the use of whole blood, or red cell concentrates in combination with plasma, 
fibrinogen, cryoprecipitate and platelets (51, 52, 80, 81). Improvements in survival rates 
have been associated with these ‘damage control’ or ‘haemostatic’ resuscitation regimens 
that have been retrospectively attributed to improvements in haemostatic function (51, 52, 
82). However a recent study by Kahn and colleagues suggests this is not the case, with 
ongoing deterioration of coagulation function evident in the face of haemostatic 
resuscitation (80). Rather than directly addressing coagulopathy it is possible that factors 
such as the prevention of haemodilution, type of injury, rate of haemorrhage, survivor bias 
or other confounders may have contributed to the survival benefits associated with 
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haemostatic resuscitation regimens (83). The optimum composition of blood products for 
resuscitation is also a point of contention, with the ratios and types of products used 
varying between countries and institutions (84-86). This divergence in clinical practice 
reflects a lack of knowledge regarding the benefits and risks of individual blood 
components in the management of ATC.   
 
2.2 The pathophysiology of Acute Traumatic Coagulopathy 
 
A combination of tissue injury and tissue hypoperfusion has been shown to be a necessary 
pre-requisite for the development of ATC in clinical studies (25, 29, 37, 39, 87-90), in vitro 
experiments (91) and animal models (29, 40, 65). A normal base deficit is not associated 
with coagulopathy in trauma regardless of the injury severity (29, 37, 92, 93). However 
systemic hypoperfusion has a dose-dependent effect on coagulation function in the face of 
tissue injury (39). ATC is most likely to occur when a base deficit of more than 6mmol/L is 
combined with an injury severity score (ISS) greater than 15, and the incidence and 
severity of coagulopathy in patients with haemorrhagic shock increases significantly when 
the ISS is 25 or greater (29).  
 
The presence of ATC is characterised by systemic hypocoagulability, dysfibrinogenaemia 
and hyperfibrinolysis (89, 94). However the underlying mechanisms triggering the 
development of ATC remain unclear and this current knowledge gap remains a key barrier 
to the development of targeted treatment strategies for this subset of patients. Protein C 
activation, tissue factor release, endothelial glycocalyx shedding, platelet dysfunction and 
fibrinolysis have all been hypothesised to play a role in the development. However the 
evidence for many of these is limited and their role in the haemostatic response to tissue 
injury and shock requires further clarification. 
 
2.2.1 Activation of the protein C pathway. 
Activation of the protein C pathway is considered by many to be instrumental to the 
development of ATC, with the accompanying protein C depletion postulated to contribute 
to the increased risk of post injury multi-organ failure and mortality (37, 38). Clinical studies 
have demonstrated a correlation between protein C reduction or activated protein C (aPC) 
increase, prolonged PT/aPTT and reduced clot strength (37-39, 95). Mechanistic 
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evaluation in a murine model of ATC has added further weight to the theory, with 
coagulopathy prevented by the administration of aPC antibodies (40).   
 
Protein C is a vitamin K dependent glycoprotein that is activated on the surface of 
endothelial cells by thrombin bound concurrently to the endothelial protein C receptor 
(EPCR) and the transmembrane glycoprotein thrombomodulin (TM) (16, 37). It is 
postulated that upregulation of TM expression occurs in response to tissue hypoperfusion 
(37, 39). When this is combined with increased thrombin generation from tissue trauma an 
increase in thrombin-TM complex formation occurs, resulting in pathological protein C 
activation (figure 4)(16). aPC then inhibits the coagulation cascade via the inactivation of 
factors Va and VIIIa and promotes fibrinolysis through the consumption of PAI-1 (figure 
5)(16, 38, 96, 97). The protein C hypothesis therefore provides an explanation for both 
systemic anticoagulation and hyperfibrinolysis, although the magnitude of these effects in 
the development of ATC has not been quantified. 
 
 
 
Figure 4. Thrombomodulin is released from activated endothelial cells and combines with thrombin 
to activate protein C. Activated protein C then inhibits coagulation by inactivating factors Va and 
VIIIa. Adapted from Brohi et al 2007 (98) 
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Figure 5. Activated protein C inhibits plasminogen activator inhibitor-1, increasing the production 
of plasmin and promoting fibrinolysis. Adapted from Brohi et al 2007 (98) 
 
The significance of the protein C pathway in ATC has recently been questioned by 
Campbell and colleagues (44) who have shown that platelet and plasma factor Va pools 
are resistant to cleavage by aPC in vitro, both at concentrations observed in trauma 
patients and following the therapeutic doses of recombinant human aPC used in sepsis. In 
addition they found no evidence of fibrinolysis, arguing that the high circulating levels of 
PAI-1 are unlikely to be inactivated to the extent required to drive the fibrinolytic picture 
seen with ATC. The application and interpretation of these findings from a static system is 
limited given the complex, dynamic process of coagulation in vivo. Further evaluation of 
the interaction between the protein C pathway, platelet function and fibrinolysis is 
warranted to better understand their contribution to ATC.  
  
2.2.2 The importance of fibrinogen and fibrinolysis 
Haemostasis relies upon fibrinogen for adequate clot formation (99). Hypofibrinogenemia 
is well documented in clinical and experimental studies of ATC, and has been correlated 
with both early and late mortality (100-103). Early fibrinogen replacement has been shown 
to improve outcomes and correct coagulopathy (87, 100, 104, 105). However there is 
controversy regarding the critical level for replacement. Levels below 2.29g/L were 
associated with increased morbidity and mortality rates in a large multicentre observational 
study (94), which is well above the threshold for replacement of 1.0 g/dL recommended by 
current guidelines (106). This incongruity reflects a lack of understanding of the underlying 
benefits and risks of fibrinogen replacement in trauma. A randomised controlled trial to 
better evaluate the role of fibrinogen replacement in trauma is in the preliminary stages 
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(107). In the interim a controlled animal model of ATC may facilitate mechanistic 
evaluation of fibrinogen replacement and improve understanding of the role of fibrinogen 
replacement in trauma. 
  
The cause of hypofibrinogenaemia in ATC is unclear. Acidosis, hypothermia and 
hemodilution have all been shown to lower fibrinogen levels (108), however these are not 
significant contributors to ATC. The formation of weak clots that are susceptible to 
increased fibrinolysis or fibrinogenolysis has been proposed as a cause (109). It is also 
possible that activation of the protein C pathway and subsequent disinhibition of the 
fibrinolytic pathways may lead to fibrinogen consumption and subsequent 
hypofibrinogenaemia (110). 
 
Fibrinolysis appears to develop in a subset of patients with ATC (39, 96, 111, 112) and is 
strongly correlated with poor clinical outcomes (96, 111-115). The CRASH-2 study 
provides level I evidence of the importance of fibrinolysis, demonstrating a significant 
survival benefit following administration of the anti-fibrinolytic tranexamic acid (TXA)(116, 
117). However a cautious approach to the empirical use of TXA is required.  As ATC 
progresses a pro-thrombotic state begins to predominate (118), with a high incidence of 
thromboembolic complications evident following major trauma (79, 119). The development 
of this pro-coagulant tendency has been attributed to inflammation, circulating 
microparticles and dysregulation of tissue factor and thrombin, which act to increase PAI-1 
production and shutdown fibrinolysis (120, 121). The survival benefits from TXA in the 
CRASH-2 study were time limited, with increased mortality rates observed if administered 
more than 3 hours following injury (116). Administration of TXA after the benefit of reduced 
fibrinolysis has passed may potentiate the prothrombotic state, increasing the risk of 
thromboembolic complications. TXA has also been shown to impede the adherence and 
transmigration of neutrophils which may have an indirect effect on outcomes (54). 
Impeding leucocyte-endothelial interactions has been shown to dampen the systemic 
inflammatory response and improve outcomes in animal models of sepsis (122, 123). 
Therefore TXA administration could theoretically play a role in decreasing the risk of 
sepsis in trauma, although stage 2 and 3 human trials have shown minimal benefit from 
these anti-adhesion therapies (123, 124). Conversely the late administration of TXA could  
theoretically contribute to an increased risk of sepsis and mortality by inhibiting the innate 
immune response, predisposing the patient to systemic bacterial infection (122). 
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The mechanism behind fibrinolysis in ATC is unclear. Increased levels of tissue 
plasminogen activator (tPA) are evident in trauma, and PAI-1 is the primary inhibitor of tPA 
(96). As previously mentioned it has been suggested that PAI-1 consumption by aPC 
might disinhibit fibrinolysis, contributing to the fibrinolytic picture observed (96, 97). Others 
argue the increased tPA levels are due to massive release following injury, which when 
augmented by increased thrombin production, catecholamine and vasopressin release 
triggers fibrinolysis (44, 125). Recent work in a rodent model has demonstrated that TEG 
detectable fibrinolysis is inhibited by tissue injury and promoted by haemorrhagic shock, 
although the hypofibrinolytic phenotype of rats makes the significance of this finding 
unclear (126). At face value it may also appear that ATC is actually DIC with a fibrinolytic 
phenotype, as the initial changes of ATC are positive on both International Society on 
Thrombosis and Hemostasis (ISTH) and Japanese Association for Acute Medicine (JAAM) 
scoring systems (125, 127, 128). However there is no histopathological evidence of 
inappropriate disseminated clot formation in trauma patients to suggest ATC and DIC are 
one and the same (129). 
 
2.2.3 Endothelial injury 
The endothelial glycocalyx is a negatively charged anti-adhesive and anti-coagulant 
surface layer that protects the endothelial cells and maintains vascular barrier function 
(130). Traumatic injury and shock result in tissue ischaemia, activation of the inflammatory 
system and stimulation of the neuro-humoral axis with a subsequent catecholamine surge 
(45, 131-134). This can lead to endothelial cell activation, glycocalyx degradation and 
luminal expression of anticoagulant/profibrinolytic proteins (45, 135) with emerging 
evidence suggesting these factors may play a role in ATC (45, 46, 132). Trauma patients 
have demonstrated an increase in syndecan-1, a soluble marker of glycocalyx shedding, 
which correlates with the severity of shock, levels of circulating catecholamines, tissue 
injury and markers of fibrinolysis (45). Elevated syndecan-1 is also associated with a 
higher incidence of ATC and mortality regardless of ISS, suggesting the downstream 
effects of trauma modulate the response rather than the injury itself (45).  
 
Endothelial glycocalyx shedding appears to trigger thrombin generation and fibrinolysis, 
which in the presence of increased soluble thrombomodulin (sTM) from damaged 
endothelial cells may enhance protein C activation (45, 135). A volume of plasma 
containing heparin like substances is also held within the glycocalyx (136), and release of 
this following degradation may lead to direct anticoagulant effects from endogenous 
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heparinisation (46). Electron microscopy data from experimental models of haemorrhagic 
shock suggests that the endothelium may be a potential therapeutic target in ATC (137).  
However further work to better evaluate the microvasculature and its role in ATC is still 
required.   
 
2.2.4 Role of platelet function and microparticles 
The cell based model of haemostasis recognizes the fundamental role of platelets in the 
balanced assembly of a fibrin clot (14), with a recent study demonstrating that platelets 
contribute to two thirds of overall clot strength (99). Minor reductions in the admission 
platelet count of trauma patients are predictive of mortality, even if they remain within the 
normal range (138, 139). Decreased responsiveness to collagen, ADP and arachidonic 
acid agonists has also been demonstrated in trauma using TEG and whole blood 
aggregometry (Multiplate), and is strongly associated with mortality (47, 48, 140). These 
observations may explain the improved outcomes associated with early platelet 
transfusion in trauma, with the degree of improvement further impacted by the quality of 
transfused platelets (85, 141, 142). 
 
The role of platelet dysfunction in ATC remains obscure. It has been suggested that initial 
platelet hyperactivation in trauma may render platelets unresponsive to subsequent 
stimulation, resulting in reduced aggregation parameters and decreased clot strength 
(143). A similar phenomenon has been observed in conditions such as transplant rejection 
and thrombotic thrombocytopaenic purpura, in which acquired defects in platelet function 
develop following prolonged activation in vivo (144). Platelet dysfunction may also play a 
role in hyperfibrinolysis. ADP release into the circulation has been shown to increase 
sensitivity to tPA, resulting in increased fibrinolytic activity (145). However mechanistic 
studies evaluating platelet function in trauma are limited and further work is required to 
better characterise the contribution to ATC. 
 
Recent work has also focused on the contribution of microparticles to coagulopathy.  
These small vesicles are derived from blood and endothelial cells and contribute to normal 
haemostatic function (146). Platelet derived microparticles (PMPs) are the most abundant 
and are highly pro-coagulant (147, 148). The PROMMT study demonstrated an 
association between decreased levels of PMPs and poor clot strength, increased blood 
product requirements and mortality in coagulopathic trauma patients (149). An alternate 
study demonstrated no significant difference in microparticle concentration with time in 
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trauma patients (150), while a third study reported elevated PMPs in trauma patients at 
hospital admission that were implicated in the development of post injury multi-organ 
failure (151). Alterations in PMP levels may be a separate component of platelet 
dysfunction developing independently to impaired aggregation capacity, and may play an 
important part in the haemostatic and inflammatory responses to trauma. However further 
work is required to determine the precise contribution to ATC. 
 
2.3 Current definitions of Acute Traumatic Coagulopathy 
 
Laboratory diagnosis is required for identification of ATC; however there remains no 
consensus regarding the laboratory definition that should be used. ATC was originally 
characterised by Brohi et al as PT > 18s, aPTT > 60s or INR >1.5 and by MacLeod et al as 
a PT >14s and aPTT > 34s (table 2)(22, 23).  Subsequent epidemiological work has found 
a 20% increase in INR to be the clinically significant threshold for blood product 
requirements and mortality, with the previously cited thresholds failing to identify 16% of 
trauma patients experiencing poorer outcomes (29). These traditional assays of 
coagulation function remain the basis for identification of ATC as they are readily available 
and have demonstrated an ability to predict mortality and need for transfusion in the 
trauma patient (25).   
 
In recent times the value of these traditional assays in the contemporary management of 
ATC has been questioned. While prolongation of these assays has been associated with 
poorer patient outcomes it is conceivable that they may simply be a marker of injury 
severity, rather than an accurate reflection of coagulation function. These tests were 
initially developed to identify specific coagulation factor deficiencies and have been shown 
to be poor predictors of haemorrhage in the face of multiple acquired deficiencies (152, 
153). The assays are performed on platelet poor plasma and reflect only the initial 20-60 
seconds of clot formation, failing to take into account the contribution of platelets to 
haemostasis, the role of fibrinolysis or thrombin generation, or the global interaction 
between coagulation enzymes (32). Furthermore the turn-around times of 30-60 minutes 
often negates the value of results in the rapidly evolving setting of acute trauma (32). This 
prolonged turnaround time could be addressed through the use of point of care (POC) INR 
devices, which have shown to correlate well with formal laboratory testing in the trauma 
setting (154-157). However the acknowledged limitations of these traditional assays 
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remain, which has precluded  widespread uptake of POC INR testing in the trauma setting 
(158). 
 
Viscoelastic coagulation testing is widely used in cardiac and transplant surgery to guide 
resuscitation, and has been associated with decreased blood product use and improved 
outcomes (159-163). These tests are performed on whole blood and produce a trace that 
is representative of [1] platelet activation, [2] thrombin burst, [3] function of plasma proteins 
including fibrinogen and [4] the fibrinolytic system (164) (figure  6).  Unlike the traditional 
assays of coagulation function viscoelastic tests provide an early and more comprehensive 
assessment of secondary haemostasis (164, 165). The need for an accurate and rapidly 
available diagnostic test of ATC has prompted the increased utilisation of viscoelastic 
testing in the trauma setting.   
 
 
Figure 6. Schematic viscoelastic trace demonstrating the commonly reported variables of TEG 
(upper part) and ROTEM (lower part).Reaction time (R)/clotting time (CT) is partially representative 
of platelet function (1), alpha angle () reflects the thrombin burst (2), maximum amplitude 
(MA)/maximum clot firmness (MCF) reflects the function of plasma proteins (3) and clot lysis 
(CL/LY) represents fibrinolysis (4). 
 
Attempts to define ATC using both rotational thromboelastometry (ROTEM) and 
thromboelastography (TEG) have been made (30-33, 166-170). ATC has a viscoelastic 
profile characterised by slow clot formation time and reduced clot amplitude (32, 33, 167-
169). ROTEM EXTEM A5 values ≤35mm have been associated with increased transfusion 
1 2 3 4 
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requirements and mortality compared to an INR > 1.2 (32, 34). Others suggest an EXTEM 
A10 ≤40mm correlates best with platelet count, fibrinogen level and blood product 
requirements (30, 170). Similar findings are evident with TEG, with maximum amplitude 
(MA) <55mm, K-time >2.5s and R value >1.1s associated with poor outcomes and 
increased need for transfusion (33, 167, 168).  However there remains no universally 
accepted viscoelastic definition of ATC (36, 93). 
 
The ability of viscoelastic testing to distinguish between different haemostatic 
abnormalities suggests that it may provide a means of individualizing haemostatic 
resuscitation in the trauma patient (33, 113). However there are no viscoelastic based 
resuscitation algorithms for trauma that have been validated by randomised trials.  
Viscoelastic tests also fail to take into account the contribution of the endothelium to 
coagulation, which may play an important role in platelet and fibrinogen function (95).  
These assays are also relatively insensitive to the detection of fibrinolysis. Over 80% of 
trauma patients with an ISS > 15 demonstrate fibrinolysis using plasmin-antiplasmin 
assays (112), however only 5-10% of these patients are detected using viscoelastic testing 
(96, 111, 112). Further work is required to identify the viscoelastic triggers that will improve 
outcomes for patients with ATC. The development of additional tests to fully evaluate 
coagulation function may be required to facilitate individualised treatment strategies for the 
trauma population. 
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CHAPTER 3: EXPERIMENTAL ANIMAL MODELS OF TRAUMATIC 
COAGULOPATHY: A SYSTEMATIC REVIEW 
 
van Zyl N, Reade MC, Fraser JF. Experimental animal models of traumatic coagulopathy: 
A systematic review. Shock 2015;44(1):16-24  
 
This paper has been reproduced in this thesis with permission from Wolters Kluwer Health. 
 
3.1 An introduction to this systematic review 
 
Pre-clinical animal research is an attractive option for evaluating the pathophysiology and 
management of ATC. The variable and dynamic nature of trauma and its management 
means that human trauma research can be limited by confounders, difficulties with patient 
recruitment and bias (56, 57). Animal models offer an alternative as they allow the 
systematic evaluation of isolated insults in vivo. This may reduce the impact of 
confounders whilst simultaneously improving mechanistic understanding. Based upon the 
perception of an iatrogenic process a number of animal models have investigated the 
effects of hypothermia, acidosis and haemodilution on systemic coagulation function (63, 
64). However to study ATC effectively animal models need to reflect our current 
understanding of the condition as an endogenous response to tissue injury and 
hypoperfusion.   
 
The use of animals for medical research has significant ethical considerations. All 
proposed animal experimentation is now appropriately scrutinised by institutional animal 
ethics committees and must encompass methods to protect and promote the welfare of 
animals (171). These methods include means to replace animals with alternatives where 
possible, reduce the number of animals used to the minimum required for statistical validity 
and refine experimental techniques to reduce the overall impact on the animals (171). 
Consideration of these ‘3R’ principles is therefore essential in the development of any 
animal study in order to maximise benefits and improve ethical acceptability.   
 
This paper addresses the first aim of this thesis:  to perform a systematic review of the 
literature in order to better inform the design of the animal model utilised in this thesis. 
Existing animal models of traumatic coagulopathy published following the recognition of 
ATC in 2003 were identified. The initiating mechanism of coagulopathy, mechanism of 
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injury, type of haemorrhage and animal species used were then assessed for clinical 
relevance, variability of response and survivability of injury. Collating this information 
identified experimental techniques that could be refined and combined in different ways in 
future animal models. It also identified data upon which to base sample size and power 
calculations, facilitating the development of a novel ovine model in an ethically acceptable 
manner 
 
3.2 Reprint of accepted manuscript. 
 
Experimental animal models of traumatic coagulopathy: a systematic review.  
Natasha van Zyl 1,2, Michael C Reade 3,4, John F Fraser 2  
1. The University of Queensland, School of Medicine, Herston, QLD, Australia  
2. Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD, Australia  
3. Burns, Trauma and Critical Care Research Centre, The University of Queensland, 
Brisbane, QLD, Australia  
4. Joint Health Command, Australian Defence Force, Canberra, Australia  
 
Abstract  
Introduction  
Perturbations in coagulation function are common following trauma and are associated 
with poor clinical outcomes. Traditionally considered an iatrogenic process, it is now 
recognized that an acute coagulation dysfunction develops prior to medical intervention. 
The mechanisms underlying the development of this acute traumatic coagulopathy (ATC) 
remain poorly understood. Pre-clinical animal research is a necessary adjunct to improve 
mechanistic understanding and management of this condition. This review aims to identify 
and evaluate existing animal models of traumatic coagulopathy for clinical relevance.  
 
Methods  
A structured search of MEDLINE/Pubmed was performed in September 2014 in 
accordance with the PRISMA guidelines.  
 
Results  
A total of 62 relevant publications describing 27 distinct models of traumatic coagulopathy 
were identified. Porcine models predominated and hemodilution in isolation or in 
combination with hypothermia and/or acidosis was the principal mechanism for inducing 
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coagulopathy. Acute coagulation changes in response to tissue injury and hemorrhage 
were evident in 5 publications, and pathophysiological evaluation of postulated 
mechanisms was performed in 3 studies.  
 
Conclusions  
There are few clinically relevant animal models that reflect the contemporary 
understanding of traumatic coagulopathy. This relative deficiency highlights the need for 
further development of valid and reproducible animal models of trauma. Well-designed 
models will facilitate improved mechanistic understanding and development of targeted 
treatment strategies for traumatic coagulopathy.  
 
Keywords: trauma, coagulation, hemorrhage, clotting function, pre-clinical research  
 
Introduction 
Trauma remains the principal cause of death and disability in people aged between 1-44 
years (1). Severe hemorrhage is the leading cause of preventable death in the trauma 
population, responsible for up to 40% of all deaths occurring within 24 hours of trauma (78, 
172). 
 
Coagulation dysfunction following trauma is well recognized and influences the ability to 
achieve effective hemostasis. Trauma induced coagulopathy (TIC) was traditionally 
attributed to the loss, dilution and dysfunction of coagulation proteases in response to fluid 
resuscitation, hypothermia and acidosis (20). However, over the past decade 
derangements in coagulation function developing independent of these factors have been 
identified in the hyper-acute post-trauma period (22, 23).  Identification of this acute 
traumatic coagulopathy (ATC) has altered the perceived natural history of TIC. The 
physiologic derangements that characterize TIC are now recognized to develop in a 
hemostatic system that is already unbalanced by an endogenous coagulation dysfunction. 
 
The reported incidence of ATC in trauma patients at hospital admission varies between 
24-41%, reflective of the multiple definitions of ATC that have been proposed  (22, 23, 29, 
39). ATC was originally characterized as a 50% prolongation in prothrombin time (PT), 
activated partial thromboplastin time (APTT) or international normalized ratio (INR) (22, 
23). More recently an INR >1.2 has been shown to be the clinically significant threshold for 
increased mortality and blood product requirements (29). The identification of ATC at 
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hospital admission continues to be based upon these traditional assays of coagulation 
function.  However these assays have limitations in the contemporary management of 
traumatic coagulopathy as they are performed on platelet poor plasma, reflect only the 
initial 20-60 seconds of clot formation and usually require 30-60 minutes for processing 
(32).  Efforts have been made to define ATC with point-of-care viscoelastic coagulation 
measurements using both thromboelastometry (ROTEM) or thromboelastrography (TEG), 
however there is no current universally accepted viscoelastic definition, assay or validated 
algorithm for ATC (30-32, 95). 
 
The pathophysiological mechanisms underlying the development of ATC remain poorly 
understood.  A combination of tissue injury and shock resulting in tissue hypoperfusion 
appears to be a necessary requirement, as neither of these insults in isolation is 
associated with deranged coagulation function (29, 37, 39). Activation of protein C (aPC) 
may play a central role by diverting hemostasis towards hypocoagulability and 
hyperfibrinolysis through the inactivation of factors Va, VIIIa and plasminogen activator 
inhibitor-1 (PAI-1) (37, 38, 40, 173). Dissenters of this theory suggest that the 
concentrations of aPC associated with ATC are insufficient to produce these effects (44). It 
has been postulated that ATC is disseminated intravascular coagulation (DIC) with a 
fibrinolytic phenotype induced by tissue factor release from the site of injury, although 
histologic evidence of DIC is absent (43, 129). There is also emerging evidence to suggest 
that platelet dysfunction and endothelial glycocalyx degradation make a significant 
contribution to ATC, with catecholamine induced endothelial damage proposed as an 
alternative initiating mechanism for coagulopathy (44-47, 132).    
 
The adverse outcomes related to ATC are not limited simply to the effects of acute blood 
loss. Coagulation dysfunction can trigger a de novo systemic inflammatory response which 
is compounded by immunologic responses to blood product transfusion and fluid 
resuscitation (49, 50). This results in an increased risk of post injury multi-organ failure, 
sepsis and thromboembolic complications in the long term (98). The current core 
therapeutic approach to patients with traumatic injury is the use of hemostatic resuscitation 
to restore circulatory homeostasis and control hemorrhage (51, 81). Whilst this improves 
mortality rates it may influence the development of a subsequent pro-coagulant state 
(121). Further improvements in patient outcomes require the development of targeted 
treatment strategies for this population, along with an understanding of when to switch 
from pro-coagulant to anti-coagulant therapies. This is currently restricted by our limited 
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knowledge of the pathogenesis of ATC and underlines the need for improved mechanistic 
understanding.     
 
The pathogenesis and management of ATC has become a prime target for pre-clinical 
research, as the nature of traumatic injury creates difficulties for human research in the 
emergency setting. Recruitment to randomized controlled trials is difficult in a population 
where treatment begins in the field and consent can be difficult to obtain, reducing study 
power and increasing the risk of bias (56).  Retrospective human studies can have multiple 
confounders, making it difficult to separate association and causation in the acutely ill 
trauma patient. They  are also reliant on the quality of available data and are associated 
with survivor bias (174).    
 
Animal models offer the opportunity to investigate isolated insults in vivo in a controlled 
and systematic fashion. This can improve mechanistic understanding of pathophysiology, 
facilitate the development of novel therapeutic strategies and provide a platform for the 
evaluation of existing and developing therapeutic interventions. While there has been 
considerable interest in developing animal models of ATC, coagulation mechanisms vary 
between species (58-60). For these models to be clinically relevant there needs to be 
more similarities than differences between the human coagulation system and that of the 
model investigated. As yet there appears no consensus as to the species, traumatic insult 
and resuscitation strategies that most closely replicate the human condition.   
 
The aim of this review was to identify the experimental animal models that have been used 
to investigate traumatic coagulopathy following the identification of ATC in 2003. The 
models were evaluated for clinical relevance, ability to characterize underlying 
pathophysiologic mechanisms and ability to evaluate the effectiveness of hemostatic 
interventions. A systematic review of the literature was performed.   
 
Methods 
Search Strategy 
The indexed online database MEDLINE/Pubmed was searched in September 2014 using 
the terms ("animals"[MeSH Terms] OR animal[All Fields]) OR preclinical[All Fields] OR 
model[All Fields] AND ("injuries"[Subheading] OR "injuries"[All Fields] OR "trauma"[All 
Fields] OR "wounds and injuries"[MeSH Terms] OR ("wounds"[All Fields] AND "injuries"[All 
Fields]) OR "wounds and injuries"[All Fields]) AND ("haemorrhage"[All Fields] OR 
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"hemorrhage"[MeSH Terms] OR "hemorrhage"[All Fields]) AND ("blood coagulation 
disorders"[MeSH Terms] OR ("blood"[All Fields] AND "coagulation"[All Fields] AND 
"disorders"[All Fields]) OR "blood coagulation disorders"[All Fields] OR "coagulopathy"[All 
Fields]).  The search was limited to studies published in English within the past 10 years to 
encompass the time period following identification of ATC.   
 
Selection criteria 
Abstracts and citations identified by the search were screened for relevance. Full 
publications of studies considered relevant were retrieved and reviewed. Additional 
relevant publications cited within the retrieved articles were also reviewed. Publications 
were included if they described an animal model of trauma or hemorrhage and reported 
systemic measures of coagulation function.  Animal models of burn injury and traumatic 
brain injury were excluded due to acknowledged differences in the processes leading to 
coagulopathy in these conditions (175, 176). 
 
Results 
The search process produced 448 abstracts, with an additional 7 relevant publications 
identified from other sources. A total of 71 publications were considered relevant and their 
full text reviewed.  Following exclusions a total of 62 publications were available for review 
(see Figure 1.)  Of these 62 publications 26 were conducted to characterize the time 
course of coagulopathy or investigate pathophysiological mechanisms associated with the 
development of coagulopathy. The remaining 36 studies aimed to investigate a therapeutic 
intervention. Many of the studies were published by the same authors or research groups 
and described previously published models with only minor variations in study protocol. 
The studies that were considered to represent an original and distinct model of traumatic 
coagulopathy are summarized in table 1.   
 
Study Characteristics 
Six different animal species were featured in the studies evaluated (see table 1). Porcine 
models predominated (n=45), with the remainder comprised of rat (n=10), rabbit (n=4), 
sheep (n=1), mouse (n=1) and hamster (n=1) models. All studies utilized general 
anesthesia administered via the intravenous, intraperitoneal and/or inhalational routes.  
 
Coagulation function was assessed by traditional plasma based assays (PT, APTT, INR, 
ACT) and/or viscoelastic assays (TEG or ROTEM). In most studies tests of coagulation 
 24 
 
function were used to establish the presence/absence of coagulopathy following the 
initiating mechanism, with repeat assessment to evaluate the coagulation response to time 
or therapeutic intervention.  Most studies also reported changes in platelet count and 
fibrinogen concentration.  Only 3 studies assessed components of the hypothesized 
mechanisms of ATC development by evaluating changes in platelet function (177), 
response to activated protein C (aPC) blockade (40) and endothelial glycocalyx thickness 
and plasma syndecan-1 (178).   
 
Methods used to induce coagulopathy. 
Iatrogenic hemodilution, hypothermia and/or acidosis were the most common mechanisms 
utilized to induce deranged coagulation function. Hemodilution prolonged routine 
coagulation assays and exacerbated hemorrhage from standardized visceral injury (179-
185). Induced hypothermia to 33oC in combination with hemodilution was correlated with a 
further increase in organ bleeding time (186, 187). Isolated hypothermia was only 
associated with prolonged coagulation assays when the tests were performed at the core 
body temperature of the animal, with no abnormalities present when performed at the 
regulation 37oC (188-190). Isolated acidosis was induced via intravenous administration of 
hydrochloric acid or cross clamping of the aorta following fixed volume hemorrhage to 
produce ischemia-reperfusion (191-194). It was associated with coagulation dysfunction 
that failed to improve following reversal with bicarbonate and the effects were 
compounded by concurrent hypothermia (193-195). 
 
Isolated hemorrhagic shock failed to significantly prolong routine coagulation assays in all 
but one study in which a 10 fold increase in APTT was observed after 60 minutes of shock 
(29, 196-198). Isolated tissue trauma was not associated with prolongation of coagulation 
assays in any study (29, 40).  One study utilized an intravenous infusion of tissue factor to 
simulate the effects of tissue factor release from the site of trauma (199). This produced 
hyperfibrinolysis, increased D dimer levels and significant prolongation of coagulation 
assays, although the absence of physical injury limits the clinical applicability of these 
findings. 
 
The combined effect of trauma and hemorrhagic shock was evaluated in 3 rodent and 7 
porcine models with varying effects on coagulation function observed (29, 40, 51, 65, 67, 
177, 200-203). All rodent models demonstrated a minimum 20% prolongation in PT, aPTT 
or PT ratio (PTr) (29, 40, 65) which was attenuated by monoclonal antibodies to aPC in 
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one study (40). One porcine model demonstrated a brief hypercoaguable response that 
was followed by significantly reduced viscoelastic function and a 20% prolongation of INR, 
although a 25% mortality rate was evident within the experimental group (67). A second 
porcine model demonstrated altered platelet function and prolonged PT that was 
exacerbated by fluid resuscitation but unaltered by induced hypothermia, although the 
initial prolongation in PT failed to attain the current clinical definition of ATC (177). Non-
significant changes in PT or INR were evident in the remaining 5 porcine models (51, 200-
203), although a significant reduction in ROTEM mean clot firmness was evident in one 
study (203) and  significant changes developed following fluid resuscitation and/or the 
induction of hypothermia and acidosis in the remaining three studies (51, 201, 202).  
 
Discussion 
This review identifies a large diversity of animal models utilized to investigate coagulation 
changes following trauma.  This may reflect both the clinical importance of such an area as 
well as the fact that the pathophysiology of ATC is poorly understood and may be difficult 
to model accurately. Despite our current understanding of the natural history of traumatic 
coagulopathy only 10 models attempted to reflect it as an endogenous dysfunction 
induced by initiating injury and hemorrhage which may be exacerbated by hypothermia, 
acidosis and hemodilution. Consequently there remains an overall lack of reproducible, 
clinically relevant models for investigating pathophysiology and evaluating therapeutic 
interventions. 
 
There are many animal models which have provided information on the effects of 
hypothermia, acidosis and hemodilution on systemic coagulation function (179-195). 
Restoration of plasma volume with crystalloid and/or synthetic colloid solutions produces a 
diffuse microvascular bleeding tendency due to dilution of clotting factors, accelerated 
endothelial glycocalyx degradation and direct interactions with fibrin polymerization (178, 
183, 204). The induction of acidosis to a pH of less than 7.2 via intravenous administration 
of hydrochloric acid or ischemia-reperfusion injury has been shown to reduce the 
enzymatic activity of coagulation proteases, producing a coagulopathy that cannot be 
readily reversed with simple correction of the acidosis (192-194). Induced hypothermia to 
less than 33oC has similar effects on coagulation protease and platelet function, 
contributing to coagulation dysfunction and exacerbating existing coagulopathy induced by 
hemodilution and/or acidosis (188-190, 195). However in the majority of models 
investigating these insults the hemodilution, hypothermia and/or acidosis precede tissue 
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injury and hemorrhage. Given our current understanding of the natural history of traumatic 
coagulopathy the clinical value and relevance of models without initiating tissue trauma 
and shock is questionable.  
 
Hemodilutional coagulopathy in isolation or in combination with hypothermia was the most 
common model used to evaluate the therapeutic efficacy of specific hemostatic 
interventions in trauma.  However in the vast majority of these models the resuscitation 
fluids used to produce hemodilution were not reflective of contemporary resuscitation 
practices (82, 205). The absence of initiating tissue injury and divergence from current 
clinical practice may limit translatability of therapeutic information obtained from these 
models. The effects of spontaneous hypothermia and acidosis are also essentially 
uncharacterized by current animal models. Changes associated with central cooling 
induced hypothermia may differ from the spontaneous hypothermia observed in human 
trauma patients given that they rarely present with a body temperature as low as 33oC 
(206). The applicability of acidosis induced by hydrochloric acid infusion or ischemia-
reperfusion in the absence of tissue trauma and shock is also dubious.  The deleterious 
outcomes associated with acidosis developing in response to tissue hypoxia and trauma 
may simply reflect the severity of the insult responsible for the acidosis rather than being a 
direct effect of the acidosis itself.  
 
The mechanism underlying the development of ATC is still incompletely understood. 
Clinical studies suggest a combination of tissue injury and hypoperfusion as a prerequisite 
(29, 37).  Animal models investigating the effects of isolated trauma and hemorrhagic 
shock support this, with altered coagulation function in response to isolated insults only 
evident in one study (196).  In contrast animal models of combined trauma and 
hemorrhage have shown varying degrees of coagulation dysfunction, which may reflect 
both the severity of the insult used and the intrinsic coagulation function of the animal.  
The majority of these models have provided information on the presence and time course 
of coagulopathy in response to trauma and hemorrhage (29, 65, 67, 177, 200, 201). 
However only 3 models have evaluated aspects of the proposed pathophysiologic 
mechanisms, and as a result animal models are yet to significantly contribute to the 
improved mechanistic understanding of ATC (40, 177, 178).   
 
Animal models of trauma enable particular clinical scenarios to be evaluated under 
controlled conditions and provide opportunities for invasive monitoring and diagnostic 
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methods that cannot be performed in human trauma patients. Incorporating techniques 
such as electron microscopy to assess the endothelial glycocalyx, organ microdialysis and 
sidestream dark field (SDF) camera application to evaluate the microcirculation and 
immunohistochemistry (IHC) to investigate tissue expression of coagulation proteases in 
conjunction with a structured coagulation component analysis will facilitate a more 
sophisticated contribution to the mechanistic understanding of traumatic coagulopathy in 
future animal models of trauma (137, 207-209). However the use of animals for trauma 
research also has limitations. The ethical necessities of sedation and anesthesia alter the 
compensatory physiologic responses to injury and have an unknown effect on the overall 
response observed (210, 211).  Animals are also genetically distinct from humans and 
demonstrate differences in coagulation assay parameters, coagulation factor 
concentrations and platelet function that may alter susceptibility to ATC (58-60).  
 
Rodent models are inexpensive and transgenic techniques such as protein C gene 
mutations provide opportunities to manipulate and evaluate isolated pathways within the 
coagulation system (212). Rodents have also consistently demonstrated the ability to 
achieve the clinical definition of ATC in response to trauma and hemorrhage (29, 40, 65). 
However rodent models are limited by animal size which restricts sample volumes and 
subsequent assays, hampering the ability to further investigate mechanisms associated 
with coagulopathy. The genomic response of mice to trauma has also been shown to 
correlate poorly with humans, bringing the clinical relevance of murine trauma models into 
question (213).   
 
Pigs are the predominant large animal species that have been used for the investigation of 
traumatic coagulopathy, which appears appropriate given the established similarities in 
cardiovascular physiology between pigs and humans (66). However pigs have 
demonstrated significant variability in coagulation function response to trauma and 
hemorrhage (51, 67, 177, 200-203).  Both viscoelastic and plasma based assays of 
coagulation function have shown pigs to be relatively hypercoaguable compared to 
humans and to have protein C levels that are only 36% of human values (58, 60). Given 
that activation of protein C is hypothesized to be a central driver of ATC, this fundamental 
difference may impede the ability to model ATC successfully in this species. The only 
porcine model to achieve the clinical definition of ATC in response to trauma and 
hemorrhage was associated with a 25% mortality rate (67). This may reflect the severity of 
the injury required to produce ATC in this species and brings into question the 
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reproducibility and ethical acceptability of this model. The abundance of porcine models 
may be limiting information about traumatic coagulopathy that could be gained from other 
large animal species. Evaluating pathophysiological mechanisms and therapeutic efficacy 
in a variety of animal species subjected to varying insults and intercurrent treatments 
would improve the translatability of results and better inform subsequent human trials 
(214) . 
 
Traumatic insults resulting in tissue damage and uncontrolled hemorrhage occur 
simultaneously in the human trauma patient. To control the degree of tissue trauma and 
shock the majority of animal models apply standardized insults in a staggered fashion and 
utilize either fixed pressure or fixed volume bleeds via an indwelling vascular catheter.  
The influence of this non-pathophysiologic sequence of insults on overall response is 
unknown. Fixed pressure hemorrhage controls the degree of hypotension via repeated 
blood withdrawal and volume replenishment; however it does not mimic the clinical 
situation and introduces the potential confounders of iatrogenic hemodilution and anti-
coagulation (29, 67). Fixed volume hemorrhage allows assessment of the hemodynamic 
responses to hypotension, although the degree of hypotension is not well defined and 
variability in the physiologic response is evident (215). Uncontrolled hemorrhage most 
closely resembles the clinical situation; however it introduces significant physiological 
variability and risk of animal mortality (189, 216-218).  This influences the repeatability of 
the model and compromises the ethical acceptability by increasing the number of animals 
required for statistically significant results to be achieved (219, 220). 
 
Existing animal models of trauma and hemorrhage demonstrate considerable variation in 
the degree of injury severity and target pressure or volume of hemorrhage (29, 40, 51, 65, 
67, 177, 200-203).  This contributes to inter-model variations in coagulation function 
response and limits the reproducibility and comparability of these existing models.  To 
improve future models of traumatic coagulopathy the degree of trauma and hemorrhage 
needs to be titrated to variables that have been shown to correlate with the onset of ATC.  
Evidence suggests that an injury severity score (ISS) of 25 combined with a base deficit of 
6mmol/L is necessary for ATC to develop (29).  While the translatability of ISS across 
species is uncharacterized, future models should aim to produce a reproducible and 
survivable tissue injury that correlates with an ISS of 25. The degree of hemorrhage 
should be titrated to a base deficit of 6mmol/L to ensure the necessary degree of tissue 
hypoxia is achieved consistently, removing the variability that may accompany a fixed 
 29 
 
pressure or volume bleed due to differences in pre-experiment fluid balance and 
physiological response (215). This should improve the clinical relevance and 
reproducibility of future animal models, facilitating more efficient inter-species comparison 
and improving the translatability of pre-clinical research.   
 
The presence of ATC was originally characterized as a 50% prolongation of PT, aPTT or 
INR (22, 23).  Subsequent epidemiological work described an INR >1.2 as the clinically 
significant threshold associated with an increased risk of adverse outcomes (29).  
However many of these patients show no clinical evidence of prolonged hemorrhage, with 
abnormalities in coagulation function only evident in laboratory assays of coagulation 
function (29).  It is possible that in these patients abnormal coagulation function develops 
as a marker of injury severity, which may explain why ATC as defined can be associated 
with an increased risk of adverse outcomes in the absence of overt clinical coagulopathic 
hemorrhage.  
 
The use of viscoelastic assays to assess coagulation function in animal models of trauma 
is increasing, which parallels the emerging role of viscoelastic assays in the acute trauma 
setting.  The use of traditional plasma based assays of coagulation function in animal 
models of trauma is appropriate given that ATC continues to be defined clinically in terms 
of these assays.  However the value of continuing to define ATC in terms of traditional 
assays has been questioned due to their inability to characterize global coagulation 
function and delayed availability of results (98).  Viscoelastic assays provide a more 
complete assessment of coagulation function via the evaluation of clot formation, clot 
strength and fibrinolytic activity and have been validated in a number of animal species 
(221, 222). However they neglect the contribution of the endothelium, which may continue 
to be a limitation given the postulated role of the endothelium in the development of ATC. 
Attempts to define ATC using viscoelastic parameters have been made, as trauma 
patients with an INR >1.2 show changes in clot formation time, clot strength and fibrinolytic 
activity (30, 32). Various thresholds have been proposed, however there is no consensus 
on the viscoelastic definition that should be used (30, 32, 33, 95). Further work is required 
to ascertain the viscoelastic triggers that identify ATC, and relevant animal models will play 
an important role in this process. 
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Conclusion 
Traditional animal models of traumatic coagulopathy were inspired by a perceived 
iatrogenic process and investigated hemodilution, hypothermia and acidosis as the 
pathophysiological initiators of coagulation dysfunction. The recognition of ATC as an 
endogenous response to tissue injury and hypoperfusion has altered the perceived 
etiology and chronology of traumatic coagulopathy. In order to be clinically relevant new 
animal models should reflect the current natural history of traumatic coagulopathy and 
utilize a variety of animal species to account for inter-species variation in coagulation 
function. 
 
Creating a clinically relevant model of trauma and hemorrhage that allows translation of 
results to humans is difficult given the complexity of the condition and known limitations of 
animal research.  It is likely that no single animal model will answer all questions and 
utilizing the appropriate model for the question at hand will continue to be a challenge. 
However preclinical animal studies are necessary to continue improving the management 
of trauma patients given the limitations of human research in the emergency setting. The 
development of a valid, reproducible and clinically relevant animal model of trauma is 
needed to contribute to improved mechanistic understanding of the pathophysiology of 
ATC and allow future evaluation of novel therapeutic agents in whole biological systems.   
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Table 1.   Distinct animal models of traumatic coagulopathy published in the last 10 years. 
Author Year of 
Publication 
Animal 
species 
Number of 
animals  per 
study arm 
Method used to induce 
coagulopathy 
Principal coagulation findings  Motivation behind study 
Martini WZ et al  
(195) 
2005 Pig 6 Combined acidosis and 
hypothermia 
Increased splenic bleeding time 
Reduced platelet count 
Increased PT and aPTT  
Increased R value on TEG. 
Pathophysiology of 
combined hypothermia 
and acidosis. 
Klemcke HG et al  
(187) 
2005 Pig 18 Combined hypothermia and 
hemodilution 
Increased PT and aPTT 
Decreased TEG  angle and maximum amplitude 
Decreased fibrinogen. 
Assess effect of 
recombinant FVIIa 
Fries D et al (180) 2005 Pig 14 Hemodilution followed by liver 
injury 
Decreased fibrinogen and platelet count 
Increased PT and aPTT  
Assess effects of 
fibrinogen concentrate 
Martini WZ et al  
(179) 
2006 Pig 6 Hemodilution Decreased fibrinogen concentration 
Reduced clotting time and clot strength on TEG. 
Pathophysiology of 
hemodilution 
Kiraly LN et al 
(216) 
2006 Pig 15 Grade V liver injury and fluid 
resuscitation 
Increased PT and aPTT  
Increased alpha angle and clotting index on TEG 
Efficacy of Hartman’s vs 
0.9%  saline resuscitation 
Martini WZ et al  
(193) 
2006 Pig 7 Isolated acidosis induced by 
hydrochloric acid infusion 
Reduced fibrinogen and platelet count 
Increased PT, aPTT and ACT 
Decreased TEG alpha angle and maximum amplitude 
Pathophysiology of 
isolated acidosis 
Martini WZ et al 
(188) 
2007 Pig 6 Isolated hypothermia (<33oC) Increased TEG clotting time and  angle  
Decreased fibrinogen concentration 
Pathophysiology of 
isolated hypothermia 
Kheirabadi B et al 
(186) 
2007 Rabbit 8 Combined hypothermia and 
hemodilution 
Increased PT and aPTT 
Decreased fibrinogen concentration 
Decreased TEG alpha angle and amplitude 
Evaluate ability of blood 
tests to detect 
coagulopathy 
Chesebro BB et al 
(40) 
2009 Mice 10 Combined laparotomy and 
fixed pressure hemorrhage 
Increase in aPTT, attenuated by monoclonal 
antibodies to activated protein C 
Contribution of protein C 
to coagulopathy. 
Cho SD et al 
(201) 
2009 Pig 37 Combined femoral fracture 
and fixed volume 
haemorrhage, hemodilution, 
induced hypothermia and 
induced acidosis 
Increased liver bleeding time 
Prolonged PT/aPTT following hemodilution 
Reduction in maximum amplitude of clot strength on 
TEG 
Reproducibility of a multi 
combat model between 
institutions 
Pragst I et al 
(181) 
2010 Rabbit 17 Hemodilution Increased kidney bleeding time 
Increased PT time 
Efficacy of prothrombin 
complex concentrate 
Frith D et al (29) 2010 Rat 10 Combined laparotomy, 
femoral fractures and fixed 
pressure haemorrhage 
Increased PTr and aPTTr Evaluate pathophysiology 
and definition of ATC 
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Iwamoto S et al 
(190) 
2010 Rat 12 Hypothermia and 
hemodilution 
Increased ACT  Pathophysiology 
White NJ et al 
(200) 
 
2010 Pig 18 Combined unilateral femoral 
fracture and fixed pressure 
hemorrhage 
Decreased fibrinogen 
No significant change in PT or aPTT 
Pathophysiology of 
combined trauma and 
hemorrhage 
Letson HL et al 
(196) 
 
2012 Rat 10 Isolated fixed pressure 
hemorrhage 
Increased aPTT Efficacy of 7.5% Na 
Adenocaine and Mg
2+ 
 
Mulier KE et al 
(202) 
2012 Pig 8 Combined lung contusion, liver 
fractures and fixed pressure 
haemorrhage 
Reduced platelet count 
Increased rate of clot formation and reduced clot 
stiffness on TEG 
Pathophysiology of multi-
trauma and haemorrhage 
Doran CM et al 
(51) 
2012 Pig 6 Combined blast injury,  fixed 
volume haemorrhage and 
hemodilution 
Increased PT  Evaluate the effect of 
targeted resuscitation 
Lesperance RN et 
al (192) 
2012 Pig 28 Fixed volume haemorrhage 
and ischemia-reperfusion 
injury 
Increased INR 
Increased CT, CFT, and reduced  angle and MCF on 
ROTEM 
Assess effects of lactic 
acidosis on coagulopathy. 
Fung YL et al 
(197) 
2013 Sheep 5 Isolated fixed volume 
haemorrhage 
No significant changes in PT or aPTT or any ROTEM 
parameters 
Evaluate the effects of 
stored blood transfusion 
Park KH et al 
(189) 
2013 Rat 8 Hypothermia and uncontrolled 
hemorrhage from splenic 
laceration 
Increased CT, CFT and reduced  angle and MCF on 
ROTEM 
Pathophysiology 
Darlington DN et 
al (65) 
2013 Rat 7 Combined femoral fracture, 
soft tissue trauma and fixed 
pressure hemorrhage. 
Increased PT and aPTT 
Decreased MCF on ROTEM 
Pathophysiology. 
Nishi K et al (218) 2013 Rat 6 Uncontrolled hemorrhage 
following tail amputation 
Prolonged ACT and clot rate following fluid 
resuscitation 
Effects of fluid 
resuscitation. 
Mohr J et al (177) 2013 Pig 10 Blunt chest trauma, liver 
laceration, fixed pressure 
hemorrhage and hypothermia 
Prolonged PT and decreased Fibrinogen 
Increased CT, CFT and reduced MCF on ROTEM 
Evaluate coagulation 
function in a multi-
trauma model. 
Hayakawa M et 
al (199) 
2013 Rat 6 Administration of tissue factor Reduced platelet count and fibrinogen. 
Increased PT and D-dimer 
Reduced anti-thrombin levels. 
Effects of tissue factor on 
coagulation and 
fibrinolysis. 
Hagemo JS et al 
(203) 
 
2013 Pig 8, 4, 2 Bilateral femoral fractures and 
soft tissue injury, fixed volume 
hemorrhage 
Decreased fibrinogen and INR. 
Increased CT on ROTEM 
 
Characterize fibrinogen 
changes with trauma and 
hemorrhage. 
Martini J et al 
(183) 
2013 Hamster 5 Hemodilution Decreased MCF and  angle, increased CFT on 
ROTEM 
Evaluate effects of 
fibrinogen on clotting. 
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Duan K et al (67) 2014 Pig 16 Right femoral fracture, small 
intestinal crush and grade III 
liver injury, fixed pressure 
haemorrhage 
Increased PT and INR 
Increased R value on TEG. 
 
Characterize changes in 
clotting function 
following trauma. 
PT=prothrombin time, aPTT=activated partial thromboplastin time, INR=International normalized ratio, TEG=Thromboelastography, ROTEM=thromboelastometry, 
PTr=prothrombin ratio, aPTTr=activated partial thromboplastin ratio, CT=clotting time, MCF=mean clot firmness, CFT=clot formation time, ACT=activated clotting time 
 35 
 
3.3 Discussion of this review article 
 
This systematic review identified 27 distinct animal models developed after 2003 to 
investigate coagulation dysfunction in trauma. Of these 27 models, 17 still utilised 
haemodilution, acidosis or hypothermia either alone or in combination as the initiating 
mechanism for coagulopathy, prior to the creation of tissue injury. This has provided 
information about the haemostatic effects of these separate insults in complex biological 
systems. However given our current understanding of the natural history of ATC the 
ongoing value of models devoid of initiating tissue injury and haemorrhagic shock is 
limited. 
 
Ten distinct animal models that investigated the combined effect of tissue injury and 
haemorrhagic shock on coagulation function were identified by this review. Three of these 
were rodent models, all of which achieved current clinical definitions of ATC using 
traditional assays of coagulation function (29, 40, 65). Elements of pathophysiology were 
examined in one of these rodent models, with coagulopathy prevented by the 
administration of aPC antibodies (40). However further evaluation of alternative 
pathophysiological mechanisms in these models was restricted by animal size, which 
limited sample collection and the number of assays that could be performed. The 
remaining 7 models were porcine models, with considerable inter-model variability in the 
coagulation function response evident (51, 67, 103, 177, 200-202). No significant change 
in coagulation function was observed in 6 of these models (51, 103, 177, 200-202). A 
statistically insignificant reduction in mean clot firmness (MCF), increase in PT and 
alteration in platelet function was observed in 2 models; however clinical definitions of ATC 
were not met until after fluid resuscitation had commenced (103, 177). The remaining 
model is the only porcine model to have achieved clinical definitions of ATC in response to 
trauma and haemorrhage alone, demonstrating a 20% increase in INR/PT (67). However 
this model was associated with a 25% mortality rate in the trauma group, creating doubt 
about the repeatability and ethical acceptability of this model. 
 
This review also highlighted a lack of consensus as to the animal species that may best 
simulate the human condition. Animals are genetically distinct from humans and 
demonstrate fundamental differences in coagulation assay parameters, coagulation factor 
levels and platelet function (58-62). These differences may alter the susceptibility to ATC 
and influence the translatability of the chosen experimental model. Refinement of future 
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animal models of ATC requires careful consideration of the chosen animal species. In 
order to be clinically relevant the chosen animal species must demonstrate more 
similarities than differences with human cardiovascular physiology and coagulation 
function.     
 
The reporting of coagulation function testing was mandated as an inclusion criterion for 
this systematic review, as the overarching aim was to inform the development of an 
alternative model of traumatic coagulopathy. However the concept of traumatic shock is 
not limited to coagulation dysfunction, as only a proportion of trauma patients demonstrate 
impaired coagulation function in response to trauma (22, 29). More broadly traumatic 
shock encompasses the local and systemic alterations that occur in response to tissue 
injury, haemorrhage, organ ischaemia, tissue reperfusion and resuscitation (223). It is 
associated with a post traumatic immune response characterised by an increase in 
inflammatory mediators and influx of inflammatory cells that predisposes to coagulopathy, 
sepsis and post-injury multi-organ failure (215, 223). The exclusion of animal models of 
trauma that failed to describe coagulation function testing is a limitation of this review, as it 
restricted the ability to fully evaluate additional information regarding traumatic shock that 
could be obtained from these other models.  
 
3.3.1 The need for an alternative large animal model 
Large animal models of coagulopathy are preferable as they facilitate sample collection 
and allow the application of standard human monitoring techniques (224). Rodent models 
are more affordable; however the ability to fully investigate pathophysiological 
mechanisms of coagulopathy in vivo is hampered by animal size. Rodents also 
demonstrate significant differences in coagulation function and the genomic response to 
trauma when compared to humans, further limiting the clinical relevance of rodent trauma 
models (58, 213). 
 
As noted in this review, pigs are the only large animal species to have been used to 
investigate the coagulation function response to trauma and haemorrhage. This may 
appear appropriate given the number of physiological similarities pigs share with humans 
(66). However pigs demonstrate significant differences in coagulation function, which may 
impact the ability to successfully model ATC in this species. Pigs are hypercoaguable 
compared to humans on both traditional plasma based assays and viscoelastic assays of 
coagulation function, and have significantly lower levels of protein C (58, 60). This may 
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explain why pig models fail to demonstrate the degree of ATC seen in rodents despite the 
use of similar protocols. The use of an alternative large animal species may therefore 
improve understanding of coagulopathy in trauma and better inform subsequent human 
studies. 
 
Sheep may represent the ideal candidate animal, as they share many similarities in 
haemodynamic, microcirculatory and immunologic function with humans (75-77).  Sheep 
have been widely used in biomedical research to model other human pathologies including 
asthma (68, 69), myocardial reperfusion (73), burn injury (225), haemophilia (226), 
osteoporosis (70), sepsis (71, 74, 227) and various presentations of acute lung injury (ALI) 
(72, 77, 228). Comparative studies of human, porcine, rodent, canine and ovine 
coagulation function using routine coagulation tests, ROTEM  and clotting factor assays 
also indicate that the human coagulation system demonstrates the greatest similarity with 
that of sheep (58, 59).   
 
3.3.2 Animal model design 
Considerable variability in the type of injury and method of haemorrhage was evident in 
the models of trauma and haemorrhage identified by this review. Hind-limb fractures 
formed the basis of tissue injury in all models, combined with varying combinations of soft 
tissue contusions (103, 200) blast injuries (51), intestinal crush injuries (65, 67), 
laparotomy incisions (29, 40) and liver injuries (67, 177, 202) to increase the degree of 
tissue trauma.  Fixed pressure haemorrhage was utilised in the majority of models (29, 40, 
65, 67, 177, 200, 202), although there was no apparent agreement with regards to the 
desired target pressure. This lack of consensus in the type of injury and degree of 
haemorrhage has contributed to inter-model variations in haemodynamic and coagulation 
function response, limiting the reproducibility and clinical relevance of these existing 
models. Targeting the severity of injury and type of haemorrhage to variables that correlate 
with the development of ATC may facilitate the development of a more clinically relevant, 
reproducible and ethically acceptable model. 
 
3.3.2.1  Severity of injury 
Retrospective human studies indicate that an injury severity score (ISS) of more than 15 is 
a necessary condition for the development ATC, with the majority of cases associated with 
an ISS > 25.(29, 39, 92, 229). The ISS was first introduced in 1974 and continues to be 
one of the most widely used measures of injury severity (230). It is based upon an 
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abbreviated injury score (AIS) which is an anatomic scoring system used to describe the 
site of injury, force applied and extent of damage (231). The ISS was introduced to take 
into account the contribution of second and subsequent injuries to morbidity and mortality 
and is calculated by assigning injuries to one of six body regions (230). The severity of 
each injury is then ranked on a scale of 1 (minor) to 5 (critical) (231). The three highest 
scores are then squared and added together to produce the ISS (table 3).  
 
The translatability of the ISS across species is yet to be characterised. However creating a 
survivable and reproducible tissue injury that correlates with an ISS of 25 may improve the 
clinical relevance of future models. Hind limb fractures would appear to be an appropriate 
basis for the tissue injury, however are insufficient in isolation as they only result in an ISS 
of 9 (table 3). Additional injuries are required to meet the proposed ISS, and the chosen 
injury needs to minimise potential confounders of uncontrolled haemorrhage, 
endotoxaemia and tissue ischaemia. Pulmonary contusions have been utilised in an ovine 
model investigating the effects of fat emboli and acute respiratory distress syndrome 
(ARDS) following femoral fracture, and have been associated with a low mortality rate 
(232). As pulmonary contusions make a significant contribution to ISS, the use of 
pulmonary contusions in conjunction with hind limb factures may facilitate the creation of a 
reproducible and survivable tissue injury that has an ISS of 25 (table 3). 
 
Table 3.  Example calculation of an ISS 
Region Injury Description AIS Highest AIS2 
Head and 
Neck 
No injury 0  
Face No injury 0  
Chest 
Multiple lung contusions 
Chest wall laceration 
4 
2 
16 
Abdomen No injury 0  
Extremity 
Displaced compound tibial 
fracture (upper third) 
3 9 
External No injury 0 0 
Injury Severity Score 25 
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3.3.2.2  Type of haemorrhage 
Retrospective human studies indicate that in the presence of severe tissue injury a base 
deficit of 6mmol/L is associated with the onset of ATC (29). This is thought to reflect 
systemic hypoperfusion developing secondary to haemorrhagic shock. In the human 
trauma patient haemorrhagic shock develops in response to uncontrolled haemorrhage, 
thus the use of uncontrolled haemorrhage in experimental models would most closely 
replicate the clinical situation. However uncontrolled haemorrhage introduces significant 
physiological variability, compromising the reproducibility of the model (189, 218). It also 
increases the risk of intra-experimental animal mortality, which would in turn impact on the 
ethical acceptability of the model. 
 
Two options for the creation of controlled haemorrhagic shock were identified by this 
review: fixed volume or fixed pressure haemorrhage. Fixed pressure haemorrhage is more 
commonly utilised by existing trauma and haemorrhage models, as it allows the degree 
and duration of hypotension to be controlled (224). However in order to maintain the mean 
arterial pressure at the target level, repeated blood withdrawal and volume replacement 
with crystalloid solutions or anticoagulated blood is required (29, 65, 67, 200). This 
increases the likelihood of iatrogenic haemodilution or anti-coagulation, and is not 
reflective of the clinical situation in the human trauma patient. Fixed volume haemorrhage 
offers an alternative, as it allows the degree of haemorrhagic shock to be controlled whilst 
facilitating assessment of the haemodynamic responses to hypovolaemia (224). This is 
more reflective of the clinical situation seen with uncontrolled haemorrhage; however it 
does increase the potential for physiological variability. 
 
3.3.3 Summary 
An alternative large animal model of coagulopathy is desirable. Pigs are the only large 
animal species that have been used to evaluate the haemostatic response to trauma and 
haemorrhage. However recognised differences in coagulation function compared to 
humans appear to be limiting the ability to successfully model ATC in this species. Sheep 
demonstrate similarities in haemostatic, haemodynamic and microcirculatory function with 
humans, suggesting they may be the ideal candidate animal in which to develop an 
alternative large animal model of ATC. Combining fixed pressure haemorrhage with a 
reproducible tissue injury that equates to an ISS of 25 may facilitate the development of a 
more clinically relevant animal model of ATC, which may improve understanding of the 
condition and facilitate future evaluation of alternative therapeutic strategies.   
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CHAPTER 4: ACTIVATION OF THE PROTEIN C PATHWAY AND 
ENDOTHELIAL GLYCOCALYX SHEDDING IS ASSOCIATED WITH 
COAGULOPATHY IN AN OVINE MODEL OF TRAUMA AND 
HAEMORRHAGE. 
 
van Zyl N, Milford EM, Diab S, Dunster K, McGiffin P, Rayner SR, Staib A, Reade MC, 
Fraser JF. Activation of the protein C pathway and endothelial glycocalyx shedding is 
associated with coagulopathy in an ovine model of trauma and hemorrhage. J Trauma 
Acute Care Surg 2016; 81(4):674-684 
 
This paper has been reproduced in this thesis with permission from Wolters Kluwer Health. 
 
4.1 An introduction to this peer reviewed publication  
 
This manuscript addresses the second and third aims of this thesis: to develop an ovine 
model of trauma and haemorrhage that demonstrates coagulation changes consistent with 
current definitions of ATC, and to observe the relationship between coagulopathy and the 
protein C pathway, endothelial glycocalyx, platelet function and fibrinolysis within this 
model.   
 
The information obtained from the systematic review discussed in Chapter 3 facilitated the 
design of the large animal model utilised in this manuscript. A need for an alternative large 
animal model was identified, with sheep chosen for their similarities with humans with 
regards to size, cardiovascular physiology and coagulation function, and the experience of 
the research group with ovine models of critical illness. Controlled haemorrhagic shock 
was created using fixed volume haemorrhage to enable assessment of the physiologic 
responses to hypovolaemia. Bilateral tibial fractures were combined with pulmonary 
contusions to produce a repeatable tissue injury that equated to an ISS of 25. A graded 
degree of injury severity was also assessed in this thesis through the inclusion of two 
different injury groups. The moderate injury group underwent bilateral tibial fractures, 
single left upper and left lower lung lobe contusions and haemorrhage of 20% blood 
volume. The severe injury group underwent bilateral tibial fractures, bilateral hamstring 
crush injuries, two left upper and left lower lung lobe contusions and haemorrhage of 30% 
blood volume. Grading the degree of trauma in this way allowed the effects on base deficit 
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and coagulation function to be assessed in a step wise manner in the hope that a more 
reproducible, clinically relevant and ethically acceptable animal model would result. 
 
The development of coagulopathy in this model was assessed using both traditional and 
viscoelastic assays of coagulation function, and the coagulation changes displayed by the 
animals are outlined in this manuscript. It was considered necessary to demonstrate 
coagulopathy consistent with INR (29), aPTT (23) and ROTEM (30) based definitions in 
order to validate this model as clinically relevant . This was achieved, with the severe 
trauma group of animals developing changes in INR, aPTT and EXTEM A10 that were 
comparable with current clinical definitions of ATC.   
 
The proposed pathophysiological contributors to ATC were then evaluated in this model.  
Changes in the protein C pathway were assessed by evaluating changes in sTM, protein 
C, aPC, factor V, factor VIII and PAI-1. A significant association between the protein C 
pathway and coagulopathy was evident, with coagulopathy correlated with an increase in 
sTM and aPC and a reduction in protein C, factor VIII and PAI-1. The contribution of the 
endothelial glycocalyx to ATC was assessed by evaluating changes in syndecan-1 and 
hyaluranon, which have been utilised as markers of endothelial glycocalyx damage in 
human studies. Coagulopathy was correlated with an increase in both syndecan-1 and 
hyaluranon in this model, further supporting the hypothesised contribution of endothelial 
glycocalyx shedding to ATC. Fibrinolysis was assessed in this model by evaluating 
changes in D-dimer levels, FIBTEM parameters. Platelet function was evaluated using  
impedance aggregometry (Multiplate analyser) with collagenase and ADP agonists. There 
was no evidence of significant fibrinolysis or altered platelet function to suggest a 
contribution to coagulopathy in this model. 
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Abstract 
Introduction: Acute traumatic coagulopathy (ATC) is an endogenous coagulopathy that 
develops following tissue injury and shock. The pathogenesis of ATC remains poorly 
understood, with platelet dysfunction, activation of the protein C pathway and endothelial 
glycocalyx shedding all hypothesized to contribute to onset.  The primary aim of this study 
was to develop an ovine model of traumatic coagulopathy, with a secondary aim of 
assessing proposed pathophysiological mechanisms within this model. 
Methods: Twelve adult Samm-Border Leicester cross ewes were anesthetized, 
instrumented and divided into three groups.  The moderate trauma group (n=4) underwent 
20% blood volume hemorrhage, bilateral tibial fractures and pulmonary contusions.  The 
severe trauma group (n=4) underwent the same injuries, an additional hamstring crush 
injury and 30% blood volume hemorrhage. The remaining animals (n=4) were uninjured 
controls.  Blood samples were collected at baseline and regularly post injury for evaluation 
of routine hematology, arterial blood gases, coagulation and platelet function, factor V, 
factor VIII, plasminogen activator inhibitor-1, syndecan-1 and hyaluranon levels. 
Results:  At 4 hours post injury a mean increase in international normalised ratio (INR) of 
20.50±12.16% was evident in the severe trauma group and 22.50±1.00% in the moderate 
trauma group.  An increase in activated partial thromboplastin time (aPTT) was evident in 
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both groups, with a mean of 34.25±1.71s evident at 2 hours in the severe trauma animals 
and 34.75±2.50s evident at 4 hours in the moderate trauma animals.  This was 
accompanied by a reduction in ROTEM EXTEM A10 in the severe trauma group to 
40.75±8.42mm at 3 hours post injury.  Arterial lactate and indices of coagulation function 
were significantly correlated (R=-0.86, p<0.0001). Coagulopathy was also correlated with 
activation of the protein C pathway and endothelial glycocalyx shedding.  Whilst a 
significant reduction in platelet count was evident in the severe trauma group at 30 
minutes post injury (p=0.018) there was no evidence of altered platelet function on induced 
aggregation testing.  Significant fibrinolysis was not evident. 
Conclusions:   Animals in the severe trauma group developed coagulation changes 
consistent with current definitions of ATC.  The degree of coagulopathy was correlated 
with the degree of shock, quantified by arterial lactate. Activation of the protein C pathway 
and endothelial glycocalyx shedding were correlated with the development of 
coagulopathy; however altered platelet function was not evident in this model. 
Keywords: Acute traumatic coagulopathy, ovine, protein C 
 
Background 
Severe hemorrhage remains the leading cause of preventable death in trauma, 
responsible for up to 40% of trauma related mortality (3). Efforts to achieve hemostasis are 
complicated by a trauma induced coagulopathy (TIC), which was traditionally attributed to 
the  loss, dilution and dysfunction of coagulation proteases secondary to hemodilution, 
hypothermia and acidosis (20). However it is now recognized that a mechanistically 
distinct acute traumatic coagulopathy (ATC) develops independent of these factors and is 
present in 24-41% of trauma patients at hospital admission (22, 23). 
 
Multiple definitions of ATC have been proposed; however there remains no consensus 
regarding the laboratory definition that should be used.  ATC was originally characterized 
as a 50% prolongation in international normalised ratio (INR) or prothrombin time (PT), or 
an activated partial thromboplastin time (aPTT) > 34s (22, 23). Subsequent 
epidemiological work has found a 20% prolongation of INR to be clinically significant for 
mortality and blood product transfusion (29).  More recently attempts have been made to 
define ATC using both thromboelastometery (ROTEM) or thromboelastography (TEG).  A 
clot amplitude < 35mm at 5 minutes (A5), <40mm at 10 minutes (A10), reaction time (R 
value) >1.1 seconds and K time >2.5 seconds have all been associated with increased 
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transfusion requirements and mortality in trauma (30-34).  However there remains no 
universally accepted viscoelastic definition of ATC. 
 
A combination of tissue injury and tissue hypoperfusion appears necessary for ATC 
development (29, 37, 39).  However the exact causative mechanisms remain poorly 
understood. Protein C activation may play a central role, with clinical studies 
demonstrating an association between protein C reduction, coagulopathy and mortality 
(37-39).  One theory is that pathological activation of protein C results in systemic 
anticoagulation and hyperfibrinolysis through the inactivation of factors Va, VIIIa and  
plasminogen activator inhibitor-1 (PAI-1) (37, 38, 40).  However the validity of this 
hypothesis has been questioned by recent in vitro work showing that factor Va pools are 
resistant to cleavage by activated protein C (aPC) at the concentrations observed in 
trauma patients (44). It has also been demonstrated that PAI-1 circulates at roughly ten 
times the concentration of aPC, raising doubts about the ability of aPC to deplete PAI-1 
levels to the extent required to accelerate fibrinolysis (41).  Consequently it has been 
suggested that increased tissue plasminogen activator release may drive fibrinolysis, and 
that ATC should instead be classified as a form of disseminated intravascular coagulation 
(DIC) with a fibrinolytic phenotype (43, 44).   There is also emerging evidence to suggest 
that platelet dysfunction and shedding of the endothelial glycocalyx may contribute to ATC, 
although the exact contributions of these factors remain unclear (45-48).   
 
There are several published porcine models that have attempted to characterize changes 
in coagulation function secondary to trauma and hemorrhage (63).  However few have 
achieved proposed definitions of ATC, and evaluation of pathophysiological mechanisms 
was limited in most cases (63).  Comparative studies of coagulation function have shown 
pigs to be relatively hypercoaguable compared to humans, which may impede the ability to 
model ATC in this species (58, 60).  The effect of non-traumatic hemorrhage of 30% blood 
volume on coagulation function has been evaluated in sheep (197); however there are no 
published ovine models evaluating the combined effects of trauma and hemorrhage .  
Sheep share a number of similarities in cardiorespiratory and hemostatic function with 
humans, demonstrating equivalent values for fibrinogen, aPTT, and ROTEM parameters 
(58, 59, 76).  These similarities suggest that they may be a suitable species in which to 
develop an alternative large animal model of ATC.     
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This study describes a model development project, with the primary aim of creating an 
ovine model of trauma and hemorrhage that developed coagulation changes consistent 
with ATC as defined by aPTT, INR and ROTEM.  The secondary aim was to observe 
associations between coagulopathy, the protein C pathway, fibrinolytic system, endothelial 
glycocalyx and platelet function within this model. 
 
Materials and Methods 
This study was approved by the University Animal Research Ethics Committee of both the 
Queensland University of Technology and University of Queensland. Experiments were 
conducted in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific purposes. Animals were housed in a dedicated facility with ad 
libidum access to food and water. Twelve female 2 year old Samm Border-Leicester cross 
sheep (weight 43.9 ± 1.2kg) were used in the study.  
 
Instrumentation and Anesthesia      
Prior to surgical intervention all animals underwent a routine health check and were fasted 
for 12 hours.  A triple lumen central line (Arrow, PA, USA) was placed in the right internal 
jugular vein for drug delivery.  Two 8.5 Fr percutaneous sheath introducers (CCombo, 
Edwards Lifesciences, Singapore) were placed in the left jugular vein for hemorrhage and 
pulmonary artery catheter placement. Anesthesia was induced with intravenous (IV) 
buprenorphine (0.01mg/kg), midazolam (0.5mg/kg) and alfaxalone (3mg/kg) and 
maintained with continuous rate infusions of alfaxalone (6mg/kg/hr), midazolam 
(0.25mg/kg/hr), fentanyl (15µg/kg/hr) and ketamine (10mg/kg/hr) with rates titrated to 
maintain surgical anesthesia.  Animals were intubated and ventilated with a Galileo 
ventilator set to 12 breaths/minute, a tidal volume of 10ml/kg and 21% FiO2 (233).  
Electrocardiogram and pulse oximetry monitoring was commenced.  A 20G cannula was 
placed in the left facial artery (Leadercath, Vygon, UK) for arterial blood pressure 
monitoring and sampling.    A pulmonary artery catheter was placed via the proximal left 
jugular sheath for monitoring of continuous cardiac output (CCO), mixed venous oxygen 
saturation (SvO2) and temperature via an Edwards Vigilance Monitor (Edwards 
Lifesciences, CA, USA), with normothermia maintained throughout. All animals received a 
500ml bolus of lactated Ringer’s solution followed by a 3ml/kg/hr infusion during the 
instrumentation period to replace estimated third space and salivary losses (234).  Splenic 
ligation was performed to attenuate physiological differences in the red cell storage 
capacity of the ovine spleen. Splenic contraction in humans has minimal effect on 
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circulating red cell mass; however splenic contraction in response to physiological stress in 
sheep can increase circulating red cell mass by up to 26% (235, 236).  Ligation was 
performed via a paracostal approach with  intrasplenic administration of  0.2ml of 1:10,000 
epinephrine prior to ligature placement to promote splenic contraction (237), maximizing 
the circulating red cell mass prior to hemorrhage. Bilateral femoral nerve blocks were 
performed using 20ml of 0.25% bupivacaine for regional anesthesia of the hind limbs.   
 
Experimental interventions. 
At the completion of instrumentation sheep were allocated to one of three groups: 
uninjured controls (n=4), moderate trauma (n=4) or severe trauma (n=4). Sample size was 
determined using a longitudinal power calculation, giving 80% power to detect a difference 
in EXTEM A10 of ≥5mm per hour between the groups.  This calculation was based upon 
EXTEM A10 as ovine reference ranges and variability have been established, and it has 
been shown to be a sensitive predictor of coagulopathy in trauma (30, 59). Crystalloid 
administration was reduced to 10ml/hr and the animals underwent an injury phase. 
Standardized 2cm x 2cm left lung lobe contusions were created through a left thoracotomy 
using a custom made pneumatic device calibrated to 15 psi (232). The moderate trauma 
sheep received single upper and lower lobe contusions, whilst the severe trauma sheep 
received two upper and lower lobe contusions.  A 20 Fr Argyle chest drain was inserted 
into the pleural space and the thoracotomy closed. A custom built guillotine device 
weighted to 8.2kg and released from a height of 1.2 meters was used to create bilateral 
tibial fractures (238). A standardized soft tissue injury was created in the hamstring region 
of the severe trauma sheep using a custom made pneumatic vice calibrated to 120psi. 
Controlled hemorrhage was performed over a 10 minute period via gravity assisted 
drainage through the distal sheath in the left jugular vein to a target of 20% blood volume 
(moderate trauma sheep) or 30% blood volume (severe trauma sheep), with blood volume 
calculated as 65ml/kg (239).  Following completion of the injury phase all groups were 
monitored for 6 hours with no further intervention and then euthanized with 10ml 
pentobarbitone sodium (325mg/ml). 
 
Sample collection and storage 
Blood samples were collected into EDTA, 3.2% sodium citrate, lithium heparin and hirudin 
blood tubes at baseline, 30 minutes post injury, then hourly post injury until completion of 
the 6 hour monitoring period.  Samples were separated and stored at -80oC pending 
analysis. ROTEM, platelet function and hematology were performed on whole blood within 
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30 minutes of collection.  Post mortem tissue samples were collected from the lungs, 
myocardium, left kidney and liver and fixed in 10% formalin.  All assays were performed 
according to manufacturer’s instructions.  
   
Coagulation function and hematology analysis 
Citrated plasma was analyzed for PT, aPTT, D-dimer levels and fibrinogen (Clauss) on the 
ACL TOP analyzer (Werfen, Sydney, Australia).  Platelet function was assessed on the 
Multiplate analyzer (Haemoview Diagnostics, Brisbane, Australia) using collagen and 
adenosine diphosphate (ADP) agonists, as trauma patients demonstrate changes in 
platelet aggregometry with these agonists, ovine reference ranges for these agonists exist, 
and ovine platelets have proven unresponsive to TRAP-6, arachidonic acid and risocetin 
agonists (48, 59). Thromboelastometry (EXTEM, INTEM and FIBTEM assays) was 
performed on the ROTEM (Haemoview Diagnostics). Full blood evaluation was performed 
using the veterinary mode of the Act Diff hematology analyzer (Beckman Coulter Australia 
Pty Ltd).   
 
Blood component analysis 
Quantitative measurements of factor V (FV), factor VIII (FVIII), protein C and PAI-1 were 
performed on citrated plasma using the ACL TOP analyzer; with protein C values 
quantified using a chromogenic assay. Soluble thrombomodulin (sTM) and aPC levels 
were measured in duplicate on EDTA plasma using commercially available immunoassays   
(Sheep soluble thrombomodulin ELISA kit, Mybiosource, San Diego USA; Sheep activated 
protein C ELISA kit, BlueGene lifesciences, Shanghai, China)  
 
Metabolic analysis 
Arterial blood samples were analyzed for pH, lactate (mmol/L), base excess/deficit 
(mmol/L) and bicarbonate (mmol/L) using an automated blood gas analyzer (ABL System 
625, Radiometer, Denmark). Plasma catecholamine levels were measured using a Waters 
2695 Separation Module (Waters Corporation, NSW, Australia). 
 
Endothelial glycocalyx evaluation 
Endothelial glycocalyx breakdown products were measured in duplicate using 
commercially available immunoassays in serum (Sheep syndecan-1/CD138 ELISA kit, 
Mybiosource, San Diego USA; Hyaluronan ELISA, Echelon Biosciences, Salt Lake City, 
USA) 
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Histology 
Formalin fixed tissue samples underwent routine processing and paraffin embedding. 4µm 
sections were cut and stained with hematoxylin and eosin.  Slides were analyzed for fat 
emboli and histological evidence of DIC (240). 
 
Statistical analysis  
Normally-distributed continuous data measurements were described using the mean and 
standard deviation.  The mean values were grouped by time points and compared for 
significant differences over time within the experimental groups using a two-way repeated 
measures analysis of variance (ANOVA).  Tukey Kramer significance adjustment was 
used to compare significant differences between groups. The relationship between data 
sets was evaluated using a two tailed Pearson correlation.  Significant differences were 
defined as a two tailed p value <0.05.  All statistical analyses were performed using 
GraphPad PRISM 6 for Windows (GraphPad Software, San Diego, USA). 
 
Results 
Hemodynamic changes 
Changes in hemodynamic parameters are depicted in figure 1.  At baseline all variables 
were comparable between the three groups.  Immediately following trauma and 
hemorrhage MAP decreased significantly from baseline in both the moderate trauma 
(116.5±4.04 to 41.25±8.60mmHg, p<0.001) and severe trauma (113±7.20 to 
30.50±4.04mmHg, p<0.001) groups, remaining significantly lower than the control group 
mean throughout the monitoring period. The mean CCO decreased from baseline 
immediately following injury in both the moderate trauma (4.5±0.58 to 3.5±0.48L/min, 
p<0.01) and severe trauma (4.25±0.96 to 3.25±0.34L/min, p<0.001) groups, returning to 
baseline levels by 4 hours. A significant rise in heart rate was evident from 1.5 hours post 
injury in both the moderate trauma (82.5±7.6 to 113.5±13.0 bpm, p=0.035) and severe 
trauma (79.0±2.6 to 116.8±19.4 bpm, p=0.033) groups. 
 
Hematology and metabolic function 
Hematology and metabolic parameters are summarized in table 1.  All groups 
demonstrated an initial rise in mean hemoglobin secondary to induced splenic contraction.  
Following hemorrhage a significant reduction in mean hemoglobin was evident in both 
trauma groups compared to the control group mean (p<0.001). The platelet count in the 
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severe trauma group was lower than control from 30 minutes post injury (p=0.018), 
however there were no significant differences in ADP or collagen-induced platelet 
aggregation between the groups. Lactate rose significantly at 1 hour post injury in the 
severe trauma group (p=0.017) and at 4 hours post injury in the moderate trauma group 
(p=0.011).  This was accompanied by a significant reduction in base excess in the severe 
trauma animals from 1-3 hours post injury, however was not associated with the 
development of a base deficit or acidosis.  The high bicarbonate levels in all animals 
suggest this may have been due to the development of a co-existing metabolic alkalosis of 
unknown cause.   
 
Coagulation function. 
Changes in coagulation function are summarized in table 2. Significant prolongation of 
aPTT was evident from 30 minutes post injury in the severe trauma group (p=0.002) and 1 
hour post injury in the moderate trauma group (p=0.011).  A significant elevation in INR 
was evident in both trauma groups at 5 hours post injury, with a mean increase from 
baseline of 20.50±12.16% in the severe trauma group and 22.50±1.00% in the moderate 
trauma group at 4 hours post injury (figure 2).  Fibrinogen decreased significantly in the 
severe trauma group compared to controls at 4 hours post injury (p=0.037). EXTEM A10 
was significantly reduced in the severe trauma group from 3 hours post injury (figure 2). 
The severe trauma group also demonstrated a significant reduction in INTEM A10 
(p=0.01) and INTEM α angle (p=0.015) compared to controls at 5 hours post injury.  
FIBTEM measurements were not significantly different between groups.  
  
Coagulation component and endothelial glycocalyx analysis 
Changes in coagulation proteases and endothelial glycocalyx markers are summarized in 
table 3. FVIII levels were reduced in the severe trauma group compared to controls from 
30 minutes post injury (p=0.002). The severe trauma group also demonstrated a 
significant reduction in FV levels from baseline over time (p<0.0001), however when 
compared to the control group a statistically significant difference was not evident.  Protein 
C levels decreased significantly in the severe trauma group compared to control from 1 
hour post injury (p=0.06), with a significant elevation in aPC levels evident from 3 hours. 
sTM levels were increased in the severe trauma group from 1 hour post injury (p<0.0001) 
and PAI-1 levels were reduced from 30 minutes post injury (p=0.006).  No significant 
change in D-dimer levels was evident.  Syndecan-1 levels were significantly elevated in 
the severe trauma group compared to the control group from 1 hour post injury (p=0.018), 
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and hyaluronan significantly higher from 3 hours post injury (p=0.018).   There was no 
significant change in plasma catecholamine levels evident.  
  
Histology 
There was no evidence of fat emboli and no evidence of perivascular hemorrhage, 
microthrombi, microinfarction, fibrin exudation or hyaline membrane formation in any tissue 
to suggest DIC.  
 
Correlations between coagulation function, metabolic function, coagulation protease and 
endothelial glycocalyx parameters in the severe trauma grop. 
Pearson correlation coefficients are outlined in table 4.  Coagulopathy as defined by 
EXTEM A10 and aPTT was strongly correlated with arterial lactate levels (p<0.0001).  
Correlation between EXTEM A10, fibrinogen concentration and platelet count was evident, 
with the reduction in fibrinogen and platelet count also correlated with the decrease in 
INTEM alpha angle.  Changes in the protein C pathway were correlated with 
coagulopathy, with the reduction in protein C, FVIII and FV correlated with both aPTT and 
EXTEM A10.  The rise in sTM and reduction in PAI-1 was also correlated with EXTEM 
A10, with the rise in aPC correlated with aPTT.  Both protein C and aPC were correlated 
with changes in INTEM alpha angle, FVIII, FV, PAI-1 and sTM.  EXTEM A10 was also 
strongly correlated with the increase in syndecan-1 and hyaluranon.  Syndecan-1, 
hyaluranon and sTM levels were correlated with the rise in arterial lactate concentration. 
 
Discussion 
This study presents the first ovine model of coagulopathy in response to trauma and 
hemorrhage, with coagulation changes in the severe trauma group consistent with current 
definitions of ATC.  An increase in aPTT to 34.25 ± 0.85 s was evident at 2 hours post 
injury, EXTEM A10 had decreased to 40.75 ± 4.21mm at 3 hours post injury and INR had 
increased by 20.50 ± 6.08% at 4 hours post injury (23, 29, 30). The model was designed to 
simulate an injury severity score (ISS) of 25 based upon evidence suggesting an ISS of 25 
is necessary for ATC to develop, and was combined with fixed volume hemorrhage to 
allow assessment of the hemodynamic responses to hypovolaemia (29).  A graded 
severity of hemorrhage was used to facilitate development of a survivable insult that 
achieved the desired end points, with a maximum volume of 30% based upon a previous 
study of non-traumatic hemorrhage (197).  Tissue hypoperfusion was evidenced by the 
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rise in plasma lactate and was correlated with the onset of coagulopathy, further 
supporting the importance of tissue hypoperfusion in the development of ATC (29). 
 
Activation of the protein C pathway has been considered instrumental to ATC, with the 
accompanying protein C depletion postulated to contribute to the increased risk of post 
injury multi-organ failure and mortality (37, 38).  Mechanistic evaluation in a murine model 
of ATC further supports this theory, with the onset of coagulopathy prevented by the 
administration of aPC antibodies (40).   Protein C is activated by thrombin bound 
concurrently to thrombomodulin and the endothelial protein C receptor (37). It is 
hypothesized that hypoperfusion results in increased thrombomodulin release from the 
endothelium, diverting thrombin away from clot formation towards the activation of protein 
C (37, 38, 40). aPC then inhibits FVa and FVIIIa, with the anti-coagulant effects of aPC 
mediated primarily through the inactivation of FVa (44).   In this study the onset of 
coagulopathy was strongly associated with activation of the protein C pathway.  The 
severe trauma animals showed a significant rise in sTM that was correlated with lactate 
levels, supporting the role of  hypoperfusion in increasing thrombomodulin release.  
ROTEM alpha angle is reflective of the thrombin burst, with the reduction in INTEM alpha 
angle in the severe trauma animals consistent with reduced thrombin activity.  This was 
correlated with the rise in sTM and aPC, suggesting diversion of thrombin towards protein 
C activation.  Inhibition of the coagulation cascade was suggested by the strong 
correlations between changes in aPC, FV and FVIII. The development of global anti-
coagulation was supported by the strong correlation between changes in protein C, aPC, 
FV, FVIII, sTM and coagulopathy as defined by both EXTEM A10 and aPTT.  This conflicts 
with published in vitro findings suggesting that FVa pools are resistant to aPC cleavage at 
the levels present in trauma patients (44).  However correlation is not proof of causation, 
and given the primary aim of this study was the development of an ovine model of 
traumatic coagulopathy no mechanistic experiments were undertaken.  Future mechanistic 
studies in this model once refined and established are indicated to better evaluate the 
contribution of the protein C pathway. 
 
A hyperfibrinolytic state has been reported to play an important role in ATC (89, 114). The 
mechanism behind fibrinolysis is unclear, with PAI-1 inhibition, tissue factor release and t-
PA production proposed as triggers (89, 199). In this study inhibition of PAI-1 was 
suggested by a reduction in PAI-1 levels that was correlated with the increase in aPC.  
The reduction in PAI-1 was also correlated with the reduction in fibrinogen and EXTEM 
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A10 values, suggesting loss of fibrinogen may have contributed to coagulopathy in this 
model.   However there was no alteration in D-dimer levels or FIBTEM parameters to 
suggest the development of overt fibrinolysis, which is consistent with published findings 
suggesting aPC is unable to inhibit PAI-1 to the extent required to produce clinically 
relevant fibrinolysis (41).  As a gradual decline in fibrinogen levels was also evident in the 
control animals in this study it is possible that endogenous hemodilution, repeated blood 
sampling and anesthesia may have contributed to the fibrinogen depletion observed.   It 
has also been proposed that ATC is actually a fibrinolytic form of DIC, as the initial 
changes are positive on International Society on Thrombosis and Hemostasis (ISTH) DIC 
scoring systems (129).  This appears unlikely given the absence of histological features of 
DIC in patients with ATC (43, 129), which was further supported by the lack of typical 
histopathological findings in this study.  
 
The endothelial glycocalyx is a negatively charged anti-adhesive and anti-coagulant 
surface layer that protects the endothelial cells and maintains vascular barrier function 
(135).  Traumatic injury and shock result in tissue ischemia, activation of the inflammatory 
system and a catecholamine surge which may lead to endothelial cell activation and 
glycocalyx degradation (45, 132, 134).  Emerging evidence suggests that these factors 
may play a role in ATC, with endothelial glycocalyx shedding associated with coagulopathy 
and mortality in trauma patients (45, 46, 132).  Degradation of the glycocalyx has been 
shown to increase local thrombin generation and fibrinolysis, which in the presence of 
increased sTM from damaged endothelial cells may enhance protein C activation (135).  A 
volume of plasma containing heparin like substances is also held within the glycocalyx, 
and release of this following degradation may lead to direct anti-coagulant effects from 
endogenous heparinisation (46).  Syndecan-1 and hyaluranon have both been utilized as 
markers of glycocalyx degradation in human studies (45, 133).  In this study both markers 
were correlated with EXTEM A10, supporting the hypothesized contribution of glycocalyx 
degradation to coagulopathy.  Rodent models of ATC suggest catecholamine excess may 
underlie glycocalyx degradation, with coagulopathy and glycocalyx shedding prevented by 
sympathetic blockade (241, 242).However this model failed to demonstrate an association 
between glycocalyx degradation and catecholamine excess.   Given the correlation 
between lactate, syndecan-1 and  hyaluranon in this study it would appear that ischemia 
secondary to hypoperfusion is the more likely trigger for glycocalyx degradation in trauma.  
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Dysfunction of platelet activation and adhesion pathways is apparent in severe trauma 
patients; however the exact contribution to ATC remains unclear (47, 243). The severe 
trauma animals in this study developed thrombocytopenia post injury, consistent with 
human findings in ATC (47), which was correlated with reductions in EXTEM A10 and 
INTEM alpha angle.  This suggests thrombocytopenia may have contributed to reduced 
clot formation and clot strength, although there was no change in induced platelet 
aggregation parameters to indicate altered function in this model.  However it has been 
demonstrated that the magnitude of ADP and collagen-induced platelet aggregation in 
sheep is less than half of that in humans, which may have contributed to the lack of 
significant findings in this model (59).    
 
Any conclusions drawn from this study should be tempered by several inherent limitations.   
In human casualties tissue damage and hemorrhage occur simultaneously.  To facilitate 
control over the degree of tissue injury and shock this model applied standardized insults 
in a staggered fashion, and the influence of this non pathophysiologic sequence on overall 
response is unknown.  The ethical necessities of sedation and anesthesia alter the 
compensatory physiologic responses to injury by reducing sympathetic activation, and 
have an unknown impact on the overall response (211). Similarities between the ovine and 
human hemostatic systems have been demonstrated (58, 59); however there are 
acknowledged differences in primary and secondary hemostasis that may impact the 
translatability of findings (59).  In human patients ATC is evident within 30 minutes of injury 
(22, 37, 89).  In this study the severe trauma animals took 2-4 hours to reach proposed 
definitions of ATC, and demonstrated variability in metabolic response.  Further refinement 
of the model is indicated to improve reproducibility and clinical relevance.  This may be 
achieved by titrating volume loss to variables shown to correlate with ATC (such as lactate 
or base deficit) rather than target volume or pressure, ensuring that the required degree of 
tissue hypoxia is consistently achieved. 
 
Conclusion 
This study presents an ovine model of coagulopathy in response to poly-trauma and 
hemorrhage.  The model demonstrates changes in INR, aPTT and ROTEM parameters 
that are consistent with current clinical definitions of ATC.  The degree of coagulopathy 
was closely correlated with the degree of shock as quantified by arterial lactate, supoorting 
the role of hypoperfusion in the development of ATC.  The hypothesized role of the aPC 
pathway and endothelial glycocalyx in ATC was also supported, with coagulopathy 
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strongly correlated with protein C depletion and markers of endothelial glycocalyx 
shedding.  With further refinement this model may facilitate mechanistic evaluation of 
hypothesized mechanisms, and enable evaluation of novel therapeutic strategies that may 
improve outcomes for trauma patients. 
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Figure 1.  Hemodynamic changes following trauma and hemorrhage.  [A] A significant reduction in 
mean arterial pressure (MAP) from baseline was evident in both trauma groups immediately post 
injury and maintained throughout the monitoring period. [B] A significant reduction in combined 
cardiac output (CCO) from baseline was evident in both trauma groups immediately post injury, 
with a return to baseline levels at 4 hours.  [C] A significant elevation in heart rate was evident in 
both trauma groups from 1.5 hours post injury 
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Figure 2.  Coagulation changes following trauma and hemorrhage.  [A] An increase in INR was 
evident in the moderate trauma (p=0.002) and severe trauma (p=0.008) groups compared to the 
control group, with a 20% increase from baseline evident at 4 hours.  [B] A reduction in EXTEM 
A10 was evident in the severe trauma group (p=0.032) from 3 hours post injury. 
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Table 1. Hematology and metabolic parameters at baseline and time points following trauma and hemorrhage.  Values are presented as mean±standard deviation  
 
Variable Baseline Post splenic 
ligation 
30 min 1 hr 2 hr 3 hr 4 hr 5 hr  6 hr 
Hb (g/L) 
Control 
Moderate 
Severe 
 
8.85±0.40 
8.38±0.30 
7.56±0.76
* 
 
10.93±0.47 
9.95±0.27 
8.97±0.85 
 
10.75±0.58 
8.38±0.28
x 
6.75±0.86
* 
 
10.60±0.50 
8.10±0.22
x 
6.43±0.66
* 
 
10.45±0.49 
7.90±0.14
x 
6.00±0.78
* 
 
10.20±0.65 
7.40±0.01
x 
5.66±0.86
* 
 
9.85±0.79 
6.98±0.10
x 
5.35±0.78
* 
 
9.55±0.89 
6.70±0.08
x 
5.20±1.12
* 
 
9.18±0.74 
6.58±0.05
x 
5.05±0.99
* 
Platelets (10
9
/L) 
Control 
Moderate 
Severe 
 
456.3±90.61 
444.5±89.08 
358.0±72.42 
(-) 
 
373.5±52.25 
346.8±56.46 
238.5±39.01
* 
 
356.5±57.38 
347.3±61.36 
229.8±46.54
* 
 
341.0±69.60 
306.3±74.44 
211.8±62.59
* 
 
337.5±54.79 
299.0±81.78 
206.0±69.78
* 
 
328.8±66.17 
300.0±86.48 
198.5±74.83
* 
 
319.0±65.67 
283.5±66.35 
205.3±84.31
* 
 
282.0±70.11 
282.0±59.23 
187.3±82.10
* 
MULTIPLATE 
ADP (U) 
Control 
Moderate 
Severe 
 
 
59.0±20.2 
65.0±21.6 
40.5±15.0 
 
 
(-) 
 
 
52.5±21.0 
54.5±22.0 
32.5±6.4 
 
 
47.8±23.4 
59.0±28.0 
40.0±2.2 
 
 
40.0±9.8 
57.8±6.4 
42.3±18.8 
 
 
44.5±15.8 
57.8±29.8 
47.0±14.6 
 
 
43.5±13.8 
67.3±29.0 
39.0±13.8 
 
 
52.5±29.3 
81.0±26.9 
40.0±12.8 
 
 
71.5±20.8 
65.3±28.8 
45.8±21.5 
MULTIPLATE 
Collagenase (U) 
Control 
Moderate 
Severe 
 
 
44.5±11.8 
36.0±15.4 
30.3±9.2 
 
 
(-) 
 
 
38.0±12.2 
26.0±13.8 
27.3±1.6 
 
 
30.8±5.0 
29.0±27.4 
26.5±9.9 
 
 
29.3±7.1 
44.5±11.4 
25.3±15.4 
 
 
29.0±12.4 
35.3±15.4 
23.0±7.6 
 
 
36.0±23.9 
34.8±15.2 
34.5±3.2 
 
 
28.0±8.2 
40.0±19.5 
22.3±7.9 
 
 
32.5±18.5 
38.5±23.5 
17.8±4.5 
Lactate(mmol/L) 
Control 
Moderate 
Severe 
 
1.23±0.38 
1.58±0.56 
1.48±0.26 
 
0.58±0.28 
0.70±0.08 
0.68±0.20 
 
0.58±0.20 
1.80±0.72 
3.50±1.08 
 
0.53±0.20 
1.88±0.74 
4.15±1.39
* 
 
0.53±0.16 
1.80±0.80 
4.68±1.93
* 
 
0.55±0.20 
1.63±0.48 
4.70±2.80
* 
 
0.50±0.14 
1.75±0.91 
5.58±4.10
* 
 
0.55±0.14 
1.80±1.02 
6.13±5.08
* 
 
0.55±0.09 
1.90±0.82 
6.73±5.30
* 
Base Excess 
(mmol/L) 
Control 
Moderate 
Severe 
 
 
2.28±2.00 
1.15±0.66 
4.65±1.85 
 
 
5.68±1.90 
2.97±1.96 
5.13±1.30 
 
 
6.20±2.02 
3.08±2.14 
1.40±3.52 
 
 
7.46±1.86 
3.53±2.96 
1.23±3.52
* 
 
 
7.43±2.02 
5.53±2.90 
1.03±5.68
* 
 
 
7.13±2.06 
5.10±2.86 
3.10±4.63 
 
 
7.35±1.95 
4.08±2.28 
3.75±1.94 
 
 
7.45±2.14 
4.15±1.62 
1.80±1.83
* 
 
 
7.58±2.62 
4.10±2.80 
1.60±1.37
* 
pH 
Control 
Moderate 
Severe 
 
7.37±0.04 
7.37±0.02 
7.49±0.04 
 
7.41±0.02 
7.40±0.02 
7.45±0.04 
 
7.41±0.02 
7.39±0.02 
7.40±0.08 
 
7.43±0.02 
7.39±0.04 
7.37±0.12 
 
7.42±0.04 
7.40±0.04 
7.37±0.10 
 
7.42±0.02 
7.39±0.04 
7.36±0.04 
 
7.42±0.02 
7.40±0.04 
7.38±0.04 
 
7.43±0.04 
7.39±0.02 
7.36±0.04 
 
7.43±0.04 
7.39±0.04 
7.38±0.06 
Bicarbonate 
(mmol/L) 
Control 
Moderate 
Severe 
 
 
26.7±2.46 
25.6±0.84 
31.4±5.72 
 
 
28.6±2.24 
28.1±0.64 
29.6±2.48 
 
 
29.7±2.16 
27.2±2.02 
29.3±1.58 
 
 
30.2±2.40 
27.7±2.68 
26.1±3.92
 
 
 
31.7±2.20 
29.6±2.72 
25.8±6.82
* 
 
 
31.6±3.02 
29.3±2.62 
25.6±3.70
*
 
 
 
31.3±2.34 
28.1±2.30 
27.0±1.78 
 
 
31.3±2.30 
28.1±1.68 
26.4±1.76 
 
 
31.5±2.66 
28.1±2.74 
28.2±3.84 
Hb = hemoglobin, Multiplate = induced platelet aggregation, (-) = not assessed, * = significant difference between control and severe trauma groups p<0.05.  x = 
significant difference between control and moderate trauma groups p<0.05 
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Table 2.  Coagulation function at baseline and at time points following trauma and hemorrhage.  Values are presented as mean ± standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Baseline 30 min 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr 
aPTT (s) 
Control 
Moderate  
Severe 
 
24.25±1.50 
23.50±2.88 
24.75±1.50 
 
23.50±1.92 
28.00±2.44 
32.50±4.20
* 
 
23.25±1.89 
30.75±4.50
x 
33.00±2.58
*
 
 
24.00±2.00 
32.00±4.97
x 
34.25±1.71
*
 
 
24.00±2.00 
32.00±4.97
x 
34.25±1.71
*
 
 
23.75±2.88 
34.75±2.50
x 
39.25±4.99
*
 
 
24.25±2.50 
35.00±2.16
x 
42.00±8.16
*
 
 
24.75±2.50 
34.50±2.88
x 
44.50±6.56
*
 
INR 
Control 
Moderate  
Severe 
 
1.43±0.06 
1.33±0.06 
1.33±0.10 
 
1.43±0.06 
1.38±0.10 
1.35±0.06 
 
1.43±0.06 
1.48±0.06 
1.38±0.10 
 
1.43±0.06 
1.48±0.06 
1.43±0.06 
 
1.45±0.06 
1.55±0.06 
1.48±0.10 
 
1.45±0.06 
1.63±0.06 
1.60±0.20 
 
1.45±0.06 
1.65±0.06
x 
1.73±0.32
*
 
 
1.45±0.06 
1.65±0.06
x 
1.80±0.28
*
 
Fibrinogen 
(g/L) 
Control 
Moderate  
Severe 
 
 
1.65±0.20 
1.78±0.18 
1.88±0.18 
 
 
1.38±0.20 
1.18±0.18 
1.48±0.22 
 
 
1.35±0.12 
1.18±0.10 
1.28±0.24 
 
 
1.43±0.18 
1.08±0.06 
1.18±0.24 
 
 
1.35±0.18 
1.10±0.02 
1.13±0.22 
 
 
1.33±0.22 
1.10±0.02 
0.98±0.20
*
 
 
 
1.30±0.18 
1.10±0.02 
0.93±0.28
*
 
 
 
1.28±0.22 
1.03±0.06 
0.85±0.20
*
 
EXTEM 
A10 (mm) 
Control 
Moderate 
Severe 
 
 
61.00±6.06 
64.50±4.20 
59.00±2.70 
 
 
55.75±4.44 
54.75±2.22 
48.50±3.42 
 
 
54.75±4.58 
53.50±2.08 
47.25±2.62 
 
 
52.00±5.94 
53.50±1.00 
45.25±2.40 
 
 
53.00±5.72 
52.25±1.50 
40.75±8.42
*
 
 
 
51.75±8.34 
49.50±2.38 
38.25±13.2
*
 
 
 
54.00±6.80 
50.25±2.50 
35.25±14.72
*
 
 
 
52.75±6.60 
49.00±2.16 
31.25±14.2
*
 
α  angle (0) 
Control  
Moderate  
Severe 
 
71.67±1.92 
72.00±4.00 
76.25±2.36 
 
66.00±17.0 
69.00±6.58 
69.50±6.02 
 
65.00±6.40 
65.50±6.66 
68.50±7.14 
 
66.00±5.90 
67.50±5.92 
66.00±9.06 
 
67.67±8.98 
71.00±8.86 
60.25±14.2 
 
69.33±5.00 
63.25±8.26 
55.75±22.10 
 
70.33±6.66 
65.25±7.28 
52.25±24.88 
 
70.67±5.56 
63.50±6.86 
47.50±25.90
*
 
CL30 (%) 
Control 
Moderate 
Severe 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
INTEM 
A10 (mm) 
Control 
Moderate 
Severe 
 
 
60.75±5.32 
64.75±3.20 
58.25±5.56 
 
 
54.00±5.56 
56.00±2.22 
53.00±2.82 
 
 
53.25±6.90 
56.50±2.38 
50.75±2.50 
 
 
53.75±6.40 
56.25±1.70 
50.00±4.24 
 
 
53.25±6.02 
54.00±1.42 
46.75±4.58 
 
 
53.25±6.76 
54.25±2.62 
44.00±8.52 
 
 
53.50±6.06 
53.00±0.82 
41.75±10.88
*
 
 
 
53.50±6.06 
53.00±0.82 
41.75±10.88
*
 
α  angle (0) 
Control 
Moderate  
Severe 
 
76.00±1.82 
73.25±3.50 
78.50±0.58 
 
68.25±5.04 
70.25±2.98 
73.25±4.37 
 
71.25±7.22 
71.25±2.98 
72.50±3.32 
 
70.75±2.98 
72.75±1.70 
70.25±2.88 
 
73.25±2.88 
70.00±3.16 
66.25±7.98 
 
71.00±3.74 
69.25±2.06 
62.50±13.53 
 
71.25±3.20 
69.00±2.44 
55.50±19.06
*
 
 
68.00±5.72 
68.50±5.74 
54.75±19.66
*
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aPTT = activated partial thromboplastin time, INR = international normalised ratio A10 = clot amplitude at 10 minutes, CL30= clot lysis index at 30 minutes,  
* = significant difference between control and severe trauma groups p<0.05.  x = significant difference between control and moderate trauma groups p<0.05 
 
 
 
 
 
 
 
 
 
 
CL30 (%) 
Control 
Moderate 
Severe 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
FIBTEM 
A10 (mm) 
Control 
Moderate  
Severe 
 
 
16.50±2.8 
18.00±3.82 
21.00±1.42 
 
 
13.25±2.76 
13.75±2.22 
16.50±2.08 
 
 
13.75±2.62 
13.25±1.90 
15.50±2.08 
 
 
13.75±1.70 
12.75±2.50 
14.50±2.64 
 
 
13.50±1.74 
12.00±2.58 
14.25±4.28 
 
 
13.25±1.26 
11.50±3.32 
12.50±3.70 
 
 
14.00±1.30 
11.75±2.06 
11.50±4.20 
 
 
13.25±2.98 
11.75±1.26 
11.75±352 
α angle (o) 
Control 
Moderate 
Severe 
 
76.75±2.06 
78.00±4.54 
79.75±0.96 
 
71.50±6.14 
72.50±4.50 
75.75±3.68 
 
73.25±3.86 
73.00±2.54 
74.75±4.72 
 
74.25±2.76 
69.75±7.64 
73.00±4.32 
 
73.75±4.04 
67.25±14.94 
69.00±10.24 
 
73.25±3.40 
68.00±7.88 
69.75±7.28 
 
76.00±1.42 
68.75±6.94 
65.75±13.82 
 
75.50±3.32 
67.75±5.68 
65.50±15.02 
CL30 (%) 
Control 
Moderate 
Severe 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
 
100 
100 
100 
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Table 3.  Coagulation protease and endothelial glycocalyx markers at baseline and time points following 
trauma and hemorrhage.  Values are presented as mean ± standard deviation 
 
 
aPC = activated protein C, PAI-1 = plasminogen activator inhibitor-1, sTM = soluble thrombomodulin,  
(-) = not assessed, * = significant difference between control and severe groups (p<0.05), § = significant 
difference from baseline. 
 
 
 
 
 
Variable Baseline 30 min 1 hr 3 hr 5 hr  
Factor VIII (U/ml) 
Control 
Severe 
 
12.05±1.44 
10.38±0.52 
 
11.2±0.58 
7.92±1.34
* 
 
10.26±1.22 
7.57±1.24
* 
 
10.70±2.04 
6.33±0.32
* 
 
10.17±1.96 
5.46±1.26
* 
Factor V (U/ml) 
Control 
Severe 
 
3.89±0.50 
4.80±2.20 
 
4.56±2.86 
2.37±0.46 
 
3.82±1.34 
2.47±0.58 
 
3.11±0.58 
2.29±0.48
§
 
 
3.34±1.18 
1.79±0.88
§
 
Protein C (mg/ml) 
Control 
Severe 
 
0.51±0.08 
0.55±0.06 
 
0.48±0.08 
0.36±0.04
* 
 
0.46±0.06 
0.32±0.06
* 
 
0.47±0.06 
0.28±0.06
* 
 
0.47±0.04 
0.22±0.06
* 
aPC (pg/ml) 
Control 
Severe 
 
278.3±35.6 
283.8±139.8 
 
(-) 
 
257.3±29.2 
462.0±158.4 
 
317.8±15.8 
589.3±203.6
* 
 
323.3±37.6 
706.3±199.4
* 
PAI-1(U/ml) 
Control 
Severe 
 
7.32±0.22 
6.84±0.70 
 
6.98±0.30 
5.96±0.14
* 
 
6.99±0.54 
5.68±0.38
* 
 
7.04±0.54 
4.69±0.38
* 
 
7.34±0.64 
4.59±0.42
* 
sTM (ng/ml) 
Control 
Severe 
 
0.89±0.12 
1.04±0.04 
 
(-) 
 
0.91±0.14 
1.61±0.12
* 
 
0.93±0.12 
1.63±0.16
* 
 
1.00±0.12 
1.88±0.32
* 
D-dimer (ng/ml) 
Control 
Severe 
 
205.25±8.62 
205.25±9.28 
 
204.50±14.24 
217.75±6.86 
 
209.00±9.02 
219.75±9.04 
 
213.50±5.98 
212.00±12.14 
 
208.75±8.54 
221.25±3.40 
Syndecan-1(ng/ml) 
Control 
Severe 
 
10.00±0.82 
10.00±0.96 
 
(-) 
 
11.25±0.50 
14.25±0.96
* 
 
10.75±0.96 
18.25±1.90
* 
 
12.00±0.82 
20.50±2.64
* 
 
Control 
Severe 
 
0.29±0.16 
0.13±0.04 
 
0.47±0.32 
1.07±0.34 
 
0.55±0.30 
1.94±0.44 
 
0.38±0.34 
2.32±1.04
* 
 
0.43±0.38 
2.04±2.54
* 
Adrenaline (nmol/L) 
Control 
Severe 
 
0.65±0.30 
0.88±0.46 
 
0.35±0.06 
0.20±0.08 
 
0.20±0.12 
0.28±0.18 
 
0.25±0.14 
0.35±0.26 
 
0.23±0.18 
0.48±0.28 
Noradrenaline 
(nmol/L) 
Control 
Severe 
 
 
6.30±1.46 
3.85±0.14 
 
 
3.43±3.00 
1.48±0.74 
 
 
1.63±0.56 
1.15±0.14 
 
 
1.83±0.54 
1.90±1.08 
 
 
1.25±0.26 
1.65±1.30 
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Table 4.  Pearson correlation coefficients for coagulation function parameters, coagulation protease levels, endothelial glycocalyx markers and platelet values in the 
severe trauma group.  
 
Parameter Lactate aPC Protein  
C 
F VIII F V PAI-1 sTM Syndecan-
1 
Hyaluranon Platelet 
count 
Fibrinogen 
EXTEM 
A10 
-0.86
**** 
-0.32 0.72
*** 
0.78
**** 
0.71
**** 
0.49
** 
-0.64
** 
-0.89
**** 
-0.93
**** 
0.81
**** 
0.78
**** 
aPTT 
0.70
**** 
0.57
* 
-0.69
*** 
-0.83
**** 
-0.75
**** 
(-) (-) 0.91
**** 
(-) (-) (-) 
Protein C -0.54
* 
-0.59
* 
(-) 0.78
**** 
0.71
*** 
0.79
*** 
-0.89
**** 
(-) (-) (-) (-) 
aPC 
0.31 (-) -0.59
* 
-0.57
* 
-0.25 -0.72
** 
0.62
** 
0.63
** 
(-) (-) (-) 
Lactate 
(-) 0.31 -0.54
* 
(-) (-) (-) 0.79
*** 
0.62
* 
0.59
* 
(-) -0.58
*** 
PAI-1 
(-) -0.72
** 
0.79
*** 
(-) (-) (-) (-) (-) (-) (-) 0.73
** 
INTEM a 
angle 
(-) -0.29 0.66
** 
(-) (-) (-) -0.69
** 
(-) (-) 0.66
**** 
0.72
**** 
 
aPTT = activated partial thromboplastin time, aPC = activated protein C, PAI-1 = plasminogen activator inhibitor-1, F VIII = factor VIII, F V = Factor V, sTM = soluble 
thrombomodulin (-) = correlation not assessed. * = p<0.05, ** = p<0.01, ***=p<0.001, ****=p<0.0001 
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4.3 Discussion of accepted manuscript 
 
At the commencement of this thesis the ability of sheep to demonstrate coagulopathy in 
response to a combination of trauma and haemorrhage had not been described in any 
available publications. The primary aim of the laboratory work performed in this thesis was 
therefore to design and develop a survivable ovine model of trauma and haemorrhage that 
demonstrated altered coagulation function in response to these insults. The observational 
assessment of proposed pathophysiological mechanisms was a secondary aim, and was 
undertaken using correlation analysis to facilitate identification of pathways, processes or 
therapeutics that may benefit from mechanistic evaluation in future studies. 
 
The type of tissue trauma and degree of haemorrhage was designed using information 
obtained from the systematic review described in Chapter 3. As the response of the sheep 
to such insults was unknown the severity of trauma was increased in a step-wise fashion 
during the model development process. This was primarily to improve the ethical 
acceptability of the proposed project, as a significant degree of animal mortality would 
have precluded the model development studies from continuing. A 6 hour monitoring 
period was included for extended assessment of changes in coagulation function, as this 
information would facilitate future model refinement. All animals included in the study were 
from the same herd of origin and demonstrated no statistically significant differences in 
baseline physiological parameters.  
 
To facilitate evaluation of ATC in this model attempts were made to minimise the impact of 
the physiological derangements of haemodilution, hypothermia and acidosis. Temperature 
was monitored throughout and normothermia maintained with the use of heating mats 
when required. A degree of endogenous haemodilution secondary to fluid shifts from 
extravascular sources was expected in the severe trauma groups secondary to 
hypovolaemia. However this was not compounded by iatrogenic haemodilution as the 
trauma animals received no fluid resuscitation, with crystalloid administration post injury 
minimised to 10ml/hr in all animals. The trauma animals also failed to demonstrate a 
significant acidosis despite the observed rise in lactate levels, most likely due to the 
development of a co-existing metabolic alkalosis of unknown cause. 
 
Sheep demonstrate a significantly lower resting haemoglobin (Hb) in comparison to 
humans (59) which results from physiological differences in splenic function. The ovine 
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spleen stores up to 26% of the circulating red cell mass and boosts circulating Hb levels 
during periods of physiological stress (236), a function that is lacking in the human spleen 
(235).  All animals in this thesis underwent a splenectomy to attenuate this difference in 
auto-transfusive capacity. The splenectomy was preceded by intra-splenic administration 
of adrenaline to induce splenic contracture (237) to increase the pre-injury Hb levels to the 
equivalent of human values. Splenectomy is a realistic component of an injury scenario 
and was considered for inclusion during the injury phase in this model without induced 
splenic contracture. However in the sheep this would also remove a variable amount of 
circulating red cell mass, which may increase variability in response and influence the 
reproducibility of the model.  As a result it was included as part of the instrumentation 
phase in this thesis. 
 
The severe trauma animals in this thesis demonstrated changes in INR, aPTT and EXTEM 
A10 at 2-4 hours post injury that were consistent with current definitions of ATC. This 
thesis therefore achieved the aim of producing an ovine model of trauma haemorrhage 
that demonstrated clinically relevant coagulation changes. However in human trauma 
patients ATC is usually evident within 30 minutes of injury (22, 89). The proposed model 
therefore has limitations, such as the time taken to achieve a clinically relevant 
coagulopathy, that indicate the need for ongoing refinement. The overall findings, 
limitations and future research directions for this model are discussed in further detail in 
Chapter 5.   
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CHAPTER 5: DISCUSSION 
5.1  Key Findings 
 
The ultimate aim of this thesis was achieved, with the creation of the first ovine model of 
trauma and haemorrhage to achieve proposed definitions of ATC. The design of the model 
was based upon a reproducible and survivable tissue injury that was equivalent to an ISS 
of 25, and was combined with fixed volume haemorrhage as it was deemed more clinically 
significant and facilitated assessment of the haemodynamic responses to hypovolaemia.  
The human dimensions of the sheep enabled more detailed observational assessment of 
proposed pathophysiological contributors than has previously been published in any other 
experimental model. This has provided further evidence of the importance of tissue 
hypoperfusion in the development of ATC, with the onset of coagulopathy strongly 
correlated with arterial lactate levels. It has also further implicated the protein C pathway 
as a key component of pathophysiology, and provided additional evidence of the possible 
contribution of endothelial glycocalyx degradation to ATC development. The findings of 
this thesis have therefore added to the understanding of ATC pathogenesis, and produced 
an experimental model that with ongoing refinement may be useful for further investigation 
of ATC and its management. These findings are discussed in further detail in the following 
sections. 
 
5.1.1 The suitability of sheep as a model of acute traumatic coagulopathy 
The success of ovine models in biomedical research is well recognised, with established 
models of critical illness and haemostatic diseases widely published. This success 
combined with established similarities with humans in coagulation parameters (58, 59), 
and haemodynamic, microcirculatory and immunological function (75-77) made them an 
attractive species in which to develop a model of ATC. A validated ovine model of blood 
transfusion also exists and demonstrates good comparability with humans in terms of red 
cell preparation, lifespan and storage lesions (244). Future evaluation of different 
haemostatic resuscitation regimens in an ovine model of ATC may therefore improve the 
translatability of results and better inform subsequent human studies.    
 
The model described in this thesis adds to the list of successful ovine models, as it is the 
first described ovine model of trauma and haemorrhage to achieve ATC as defined by 
INR, aPTT and EXTEM A10. It is also the first large animal of trauma and haemorrhage to 
achieve proposed clinical definitions of ATC without associated mortality in the injury 
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group(s). The aim of creating a survivable tissue injury that was equivalent to an ISS of 25 
was therefore achieved. This may have been facilitated by the established similarities 
between human and ovine coagulation function (58, 59). The severity of tissue injury and 
degree of haemorrhage required to produce a clinically relevant response in sheep may 
have been less than in other species that demonstrate established differences with human 
coagulation function. 
 
The similarities in size between humans and sheep allowed standard human monitoring 
equipment to be utilised, which provided detailed information on the haemodynamic 
responses to trauma and haemorrhage in this model. Collection of multiple blood samples 
throughout the study period was also possible due to animal size, allowing more in depth 
evaluation of proposed pathophysiological mechanisms. As a result the model utilised in 
this thesis is the only animal model of ATC to have evaluated aspects of all major 
hypothesised pathophysiological contributors (table 4).   
 
Table 4. Hypothesised pathophysiological mechanisms evaluated in animal models of 
trauma and haemorrhage that achieve clinical definitions of ATC. 
Author Animal 
Species 
Coagulation findings Pathophysiological features 
evaluated 
van Zyl et al Sheep 20% increase in INR 
aPTT > 34s 
EXTEM A10 < 40mm 
Protein C pathway (aPC, FV, FVIII, 
PAI-1, sTM) 
Glycocalyx (syndecan-1, hyaluranon) 
Fibrinolysis (D-dimer, FIBTEM, 
Fibrinogen, Histology) 
Platelet function (Multiplate induced 
aggregation testing) 
Hypoperfusion (Lactate, Base deficit) 
Duan et al Pig 20% increase in 
INR/PT 
Prolonged R value 
Fibrinolysis (ATIII, Fibrinogen, D-
dimer 
Hypoperfusion (Lactate, Base deficit) 
Darlington et al Rat PT > 18s 
aPTT > 24s 
Decreased MCF 
Hypoperfusion (Lactate, Base deficit) 
Fibrinolysis (Fibrinogen, FIBTEM) 
Frith et al Rat PTr = 1.3 Hypoperfusion (Lactate, Base deficit) 
 
Chesebro et al Mouse aPTT > 34s Hypoperfusion (Lactate, Base deficit) 
Protein C pathway (Monoclonal 
protein C antibodies) 
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5.1.2 Tissue hypoperfusion, blood lactate levels, base deficit and coagulopathy. 
Epidemiological work strongly suggests that the development of ATC requires a 
combination of tissue injury and tissue hypoperfusion., with coagulopathy most likely to 
occur if an ISS >15 is combined with a base deficit of > 6mmol/L (29). Retrospective 
studies and experimental models support this finding, with coagulopathy not developing in 
the presence of normal base deficit, regardless of the injury severity score (29, 37, 92, 93). 
 
The findings of this thesis further support the role of hypoperfusion in the development of 
coagulopathy. Tissue hypoperfusion causes inadequate oxygen delivery to the tissues, 
forcing the onset of anaerobic metabolism that leads to the accumulation of lactic acid 
(245). The severe trauma group in this thesis demonstrated a strong correlation between 
coagulopathy as defined by both aPTT and EXTEM A10 and arterial lactate levels.  
However the severe trauma animals did not develop an associated base deficit or acidosis 
despite the significant rise in arterial lactate. Base deficit is mechanistically linked to 
arterial lactate levels, and is often used as a surrogate marker for the accumulation of 
lactic acid as it has been shown to correlate with arterial lactate in animal models of shock 
(246). However clinical studies evaluating trauma and critical illness have shown poor 
correlation between base deficit and arterial lactate levels (245, 247, 248). Clinical studies 
have also shown arterial lactate to be a strong predictor of outcomes such as mortality and 
need for resuscitation in trauma (249, 250), and arterial lactate was a better predictor of 
haemorrhage severity than base deficit in an LD50 model of penetrating trauma (251).  
There are no publications that assess the sensitivity of arterial lactate as a predictor of 
ATC. However in the trauma animals in this thesis arterial lactate appeared to be a better 
predictor of coagulopathy than base deficit.   
 
All animals in this thesis (including controls) demonstrated a significant increase in 
bicarbonate levels during the experimental period, suggesting the development of a 
metabolic alkalosis. It is likely that a co-existing metabolic alkalosis in the trauma sheep 
blunted the changes in base deficit expected to accompany the observed rise in blood 
lactate levels. The cause of the metabolic alkalosis in the animals used in this thesis is 
unknown. The development of a metabolic alkalosis has been seen previously in sheep 
using alternate forms of total intravenous anaesthesia (252, 253), and while there are no 
published reports associated with alfaxalone it is possible it may be secondary to the 
anaesthetic agent. Sheep do also demonstrate significant salivary and ruminal losses 
during anaesthesia (254). Ruminant foregut physiology would suggest that these losses 
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should be pH neutral or high in bicarbonate, which should not trigger the development of a 
metabolic alkalosis (254, 255). However no analysis of the gastric losses from the animals 
used in this thesis was undertaken. Movement of acid from the abomasum towards the 
rumen may have occurred, resulting in acid losses and triggering the development of 
alkalosis.  Further investigation of these changes should be considered in future studies. 
 
5.1.3 Changes in coagulation function 
Coagulation function within this model was assessed using both traditional plasma based 
assays and viscoelastic assays of coagulation function. This was in keeping with the 
multiple proposed definitions of ATC, and the traditional and contemporary assessment of 
coagulation dysfunction in the trauma patient (22, 23, 29-34). ATC was originally 
characterised using PT, aPTT and/or INR, and these tests remain the current standard for 
establishing a definitive diagnosis of coagulopathy. Studies suggest PT/INR to be more 
sensitive indicators of coagulopathy in trauma (256, 257), whilst aPTT appears to be more 
specific (98). However these traditional assays were originally developed to identify 
specific factor deficiencies within the extrinsic or intrinsic pathways of coagulation resulting 
from heritable coagulopathies or anticoagulant therapy (258). They have been shown to 
correlate poorly with bleeding risk in patients undergoing elective surgical procedures 
(259), and as they require 30-60 minutes for processing they may not accurately reflect the 
rapidly evolving coagulation status of the trauma patient (33). This has led to the 
increasing use of viscoelastic testing in the trauma setting, as EXTEM A5 and A10 and 
FIBTEM A5 have all shown to be sensitive predictors of coagulopathy (30, 32, 34).   
 
Assessment of INR within this model was performed using both formal laboratory testing 
and a point of care (POC) measuring device (Coaguchek XS System, Roche Diagnostics, 
NSW, Australia). The accuracy of POC devices in the evaluation of traumatic 
coagulopathy in the emergency setting has been assessed in retrospective and 
prospective studies (154-158). In the majority of these studies the results from the POC 
device were well correlated with formal laboratory tests, allowed rapid availability of results 
and appeared cost effective (154-157). The rationale behind the use of POC devices in 
this thesis was twofold. Firstly it was to provide some immediate feedback with regards to 
INR levels during the experimental period, which assisted with the model development 
process. Secondly it was to evaluate the correlation between POC and laboratory INR 
values in this experimental model. The results from the POC device were well correlated 
with the results from the formal laboratory tests within this model (figure 7). This is 
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consistent with findings in human studies and suggests that POC INR devices may play a 
role in the early identification of the coagulopathic trauma patient, particularly in the pre-
hospital setting or in facilities that are unable to access viscoelastic point of care testing.   
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Figure 7.  A strong correlation between laboratory and point of care INR measurements was 
evident in the severe trauma group (R=0.8746, p<0.0001) 
 
The severe trauma animals in this thesis demonstrated significant changes in ROTEM 
EXTEM A10 values compared to controls, with proposed definitions of ATC achieved at 3 
hours post injury (30). Changes in EXTEM A10, EXTEM A5 and FIBTEM A5 values on 
ROTEM have been shown to be strongly predictive of massive transfusion in trauma in 
observational studies (30, 32, 34). FIBTEM A5 appeared the most sensitive predictive 
measure in one study, leading to suggestions it should be used in combination with 
EXTEM A10 or A5 in the detection and resuscitation of the coagulopathic trauma patient. 
(34). However it is recognised that significant fibrinolysis appears to develop in a subset of 
patients with ATC (39, 96, 111, 112), and the sensitivity of FIBTEM A5 is likely to be 
highlighted in this group.  In this thesis there were no significant changes in any FIBTEM 
parameters or D-dimer levels, suggesting fibrinolysis did not make a significant 
contribution to the coagulopathy observed in the proposed model. The presence of 
fibrinolysis in trauma has been associated with a higher ISS and base deficit (89, 111), 
and it is possible that the aim of developing a survivable injury in this thesis inhibited the 
development of a model that demonstrated significant fibrinolysis. It has also been 
demonstrated that FIBTEM assays are relatively insensitive to fibrinolysis, detecting only 
10% of patients with plasmin-antiplasmin complex confirmed fibrinolysis (112). Additional 
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testing is therefore warranted in future studies to better characterise fibrinolysis and its 
contribution to ATC. 
 
5.1.4 The contribution of the protein C pathway. 
A strong association between coagulopathy and the protein C pathway was evident in the 
model described in this thesis. The degree of coagulopathy was correlated with an 
increase in sTM and aPC, and a decrease in protein C, factor V, factor VIII and PAI-1 
levels in the severe trauma animals. This suggests protein C activation, inhibition of the 
coagulation cascade and the onset of global anti-coagulation (37-39). These findings 
support existing evidence suggesting that activation of the protein C pathway may play a 
significant role in the development of ATC (37-40). 
 
Protein C is a systemic antiocoagulant that is proteolytically converted to an active form by 
thrombin bound concurrently to TM and the EPCR (16, 37).  Once activated it proceeds to 
inactivate factors Va and VIIIa and deplete PAI-1 (16, 260). Activation of the protein C 
pathway serves two primary protective functions.  The first is inhibition of systemic 
thrombosis following tissue injury through the binding of thrombin to constitutively 
expressed thrombomodulin on undamaged endothelial cells (17, 260). The second is 
inhibition of local thrombosis during periods of hypoperfusion via the increased expression 
of thrombomodulin on activated endothelial cells (16, 17).   
 
The proposed trigger for the pathological activation of protein C in ATC is the widespread 
release of thrombomodulin from endothelial cells in response to tissue hypoperfusion (37).  
Clinical evidence has demonstrated that systemic hypoperfusion is associated with an 
increase in sTM levels (37, 89). This was supported by the findings of this thesis, with the 
severe trauma animals demonstrating a significant rise in sTM levels that was correlated 
with arterial lactate measurements. Furthermore the rise in sTM observed in the severe 
trauma animals was correlated with protein C depletion, aPC rise and degree of 
coagulopathy. There is some debate in the literature regarding the relationship between 
sTM and endothelial bound thrombomodulin (eTM), with studies variously suggesting that 
sTM may reflect overall TM activity (261, 262), inhibit the action of eTM (263, 264) or act 
simply as a marker of endothelial injury (265). However the association between sTM and 
aPC levels in this thesis suggests that sTM levels reflect overall thrombomodulin activity. 
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Widespread activation of protein C impairs thrombin utilisation, resulting in impaired clot 
formation. ROTEM EXTEM A10 provides a quantitative assessment of mean clot firmness 
(164, 165), and the reduction in EXTEM A10 in this ovine model provides evidence of 
impaired clot formation. The correlation between aPC and EXTEM A10 values in this 
thesis suggests that aPC may have contributed to this finding. Protein C activation also 
results in consumption of PAI-1, which may cause uninhibited tPA mediated conversion of 
plasminogen to plasma. In this thesis a decrease in PAI-1 was correlated with the increase 
in sTM and aPC levels, suggesting that activation of protein C may have triggered PAI-1 
inhibition. However there was no evidence of overt fibrinolysis in this thesis, which is 
consistent with suggestions that aPC is unable to PAI-1 to the extent required to produce a 
clinically relevant fibrinolysis (41). 
 
5.1.5 The contribution of the endothelial glycocalyx 
The endothelial glycocalyx is a layer of cell bound proteoglycans and glycoproteins that 
acts as a key regulator of vascular permeability, cell adhesion and inflammation (130, 266, 
267). The major constituents of the endothelial glycocalyx are syndecan, hyaluronic acid, 
chondroitin sulphate and heparin sulphate (266, 267). Disruption of the endothelial 
glycocalyx leads to endothelial cell activation, platelet adhesion and the expression of 
anticoagulant or pro-fibrinolytic proteins (130, 268, 269). 
 
An increase in syndecan-1 has been associated with coagulopathy and mortality in trauma 
patients, suggesting that degradation of the endothelial glycocalx may contribute to the 
development of ATC (45, 46, 132). The findings of this thesis further support this 
hypothesis, with both syndecan-1 and hyaluronon correlated with the degree of 
coagulopathy as measured by EXTEM A10 and aPTT. However the mechanism by which 
endothelial glycocalyx shedding contributes to coagulopathy is still unclear. A volume of 
plasma containing heparin like substances is also held within the glycocalyx, and release 
of this following degradation may have direct anticoagulant effects from endogenous 
heparinisation (46). An alternative hypothesis is that shedding triggers increased 
fibrinolysis and thrombin generation, which in the presence of increased thrombomodulin 
from endothelial cell damage may trigger protein C activation and global anticoagulation 
(45, 135). Further work to better evaluate the mechanistic contribution of the 
microvasculature in ATC is therefore indicated. 
 
 70 
 
Traumatic injury and haemorrhagic shock result in tissue ischaemia, activation of the 
inflammatory system and stimulation of the neuro-humoral axis with a subsequent 
catecholamine surge (45, 131-134). Changes in the endothelial glycocalyx in trauma have 
predominately been attributed to this catecholamine surge, with sympathetic blockade 
effective in preventing coagulopathy and endothelial glycocalyx shedding in rodent models 
of haemorrhagic shock (241, 242). However this finding was not supported in this thesis.  
No elevation in plasma catecholamine levels was evident in either trauma group, and there 
was no association between glycocalyx degradation and catecholamine levels evident on 
correlation analysis. Instead the increase in both syndecan-1 and hyaluronon was strongly 
correlated with arterial lactate levels. Ischaemia has been shown to be a significant trigger 
for endothelial glycocalyx degradation in patients undergoing vascular surgery (134). The 
findings of this thesis suggest that ischaemia secondary to hypoperfusion may have been 
the trigger for endothelial glycocalyx degradation in the severe trauma animals. It is 
therefore possible that tissue hypoperfusion rather than catecholamine excess is the 
trigger for endothelial glycocalyx degradation in trauma patients. 
 
5.1.6 Altered platelet function did not contribute to coagulopathy in this model 
The cell based model of haemostasis recognises the fundamental role of platelets in the 
balanced assembly of a stable fibrin clot (14). Trauma patients demonstrate decreased 
responsiveness to platelet aggregation testing, leading to speculation that dysfunction of 
platelet activation and adhesion pathways may contribute to ATC (47, 48, 140). However 
differences in platelet function may exist between platelets at the site of injury and the 
circulating platelet pool (270), with further evaluation required to ascertain if circulating 
platelets truly reflect active platelet function.   
 
In this thesis the severe trauma animals developed significant thrombocytopaenia 
immediately post injury which persisted throughout the monitoring period. This is 
consistent with human findings in ATC, in which minor reductions in the admission platelet 
count are predictive of mortality (138, 139). Thrombocytopaenia in the severe trauma 
animals was correlated with the reduction in EXTEM A10 and INTEM alpha angle, which 
suggests that thrombocytopaenia may have contributed to reductions in clot formation and 
clot strength. However there was no associated change in induced platelet aggregation 
parameters to suggest altered platelet function. Constitutional differences in platelet 
function may have contributed to this finding as the magnitude of ADP and collagen 
induced platelet aggregation in sheep is less than half that of humans (59). It is possible 
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that a significant alteration in platelet function did develop, however was unable to be 
detected by the tests utilised in this thesis.  
 
5.1.7 Limitations of the model used in this thesis 
Pre-clinical animal research will always have associated limitations, and the model used in 
this thesis is no different. The lack of catecholamine release by the trauma animals in this 
thesis suggests that the ethical necessities of sedation and anaesthesia may have 
significantly altered the compensatory physiological responses to injury (211), impacting 
on the overall response that was observed. In contrast to human trauma patients who 
simultaneously experience tissue injury and uncontrolled haemorrhage, this thesis applied 
standardised insults in a staggered fashion to control the degree of trauma and 
haemorrhage experienced by the animals. This non-pathophysiological sequence of 
events may have also influenced the overall response observed by further impacting on 
the compensatory response to injury in the trauma animals.    
 
Sheep are genetically distinct from humans, and despite demonstrable similarities in 
coagulation function also have acknowledged differences in primary and secondary 
haemostasis that may impact the translatability of findings (58, 59). These differences 
include constitutively different concentrations of coagulation factors, with mean protein C 
activity that is 60% of human values and mean factor VIII  activity that is three times those 
of humans (59) (table 5). Sheep also demonstrate significant differences in platelet 
response to induced aggregation testing. Ovine platelets have proven unresponsive to 
TRAP-6, arachidonic acid and risocetin agonists and show less than 50% of the human 
response to ADP and collagen agonists (59, 62) (table 5), which may make it difficult to 
accurately assess the contribution of platelet dysfunction to coagulopathy in this model. 
 
Table 5. Ovine ranges for selected coagulation parameters compared to human reference ranges. 
Coagulation test Sheep (SBL) 
Mean ± SD 
Human 
Reference Range 
Protein C activity (%) 48.6±9.3 70-140 
Factor VIII activity (%) 816.9±201.4 50-150 
ADP  induced platelet aggregation (U) 38±20 57-113 
Collagen induced platelet aggregation (U) 41±19 72-125 
ADP=adenosine diphosphate, SBL = Samm Border Leisceter.  All values taken from Foley et al 2014 (54) 
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ATC develops within 30 minutes of injury in human patients (22, 37, 89). In this thesis a 
significant prolongation of aPTT was evident within 30 minutes of injury in the severe 
trauma animals, however proposed definitions of ATC were only achieved at 2-4 hours 
following injury. The severe trauma animals also demonstrated variability in haemostatic 
and metabolic responses to injury. One animal become noticeably more unwell than the 
other animals in the group, demonstrating a much higher rise in plasma lactate 
concentration and INR and greater reduction in EXTEM A10 (see appendix 7.1.1). The 
results reported for this study included this animal because power calculations required a 
minimum of 4 animals and it was felt 3 animals were insufficient to give valid quantitative 
results. However the impact of this animal on overall results was assessed by performing a 
basic secondary statistical analysis with this animal removed (see appendix 7.1.2). A 
statistically significant difference in EXTEM A10, aPTT and INR was maintained following 
removal of this animal, although a difference in the time point at which statistical 
significance was achieved was evident. Variability of response can be expected in any in 
vivo study and is taken into account when performing power calculations, particularly given 
the need to minimise the number of animals required for statistical validity (271). However 
the degree of variability in the severe trauma animals in this study was unexpected. Both 
the variability in response and the time taken to achieve clinical definitions of ATC indicate 
that further refinement of the model is required to improve clinical relevance and 
reproducibility for future studies.  
 
5.2 Future research direction 
 
5.2.1 Refining the proposed model 
The overarching aim of this thesis was the development of an ovine model of trauma and 
haemorrhage that demonstrated coagulopathy consistent with current definitions of ATC.  
This aim was achieved with the severe trauma group demonstrating an increase in aPTT 
to 34.25 ± 0.85 s at 2 hours post injury, decrease in EXTEM A10 to 40.75 ± 4.21mm at 3 
hours post injury and increase in INR by 20.50 ± 6.08% at 4 hours post injury (23, 29, 30).  
This confirms our supposition that sheep may be a suitable species for the development of 
a large animal model of ATC. However as mentioned in the previous section ATC is 
usually evident in human patients within 30 minutes of injury. The time taken for a clinically 
relevant coagulopathy to develop in the model used in this thesis, and the variability of 
response evident in the severe trauma animals indicates that ongoing model refinement is 
required to improve reproducibility and clinical relevance. 
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Fixed volume haemorrhage was used in this model as it was felt it more closely mimicked 
the clinical situation, and facilitated the assessment of the haemodynamic responses to 
hypovolaemia (215). However haemorrhage of 30% blood volume in this model failed to 
produce a significant change in pH or base deficit which suggests that an increase in 
volume loss is indicated. However estimating the degree by which volume loss needs to 
be increased is difficult given the variability in response that was observed in the severe 
trauma animals. As the volume removed was based upon body weight the pre-
experimental state of the animal influenced the degree of blood loss. All animals used in 
this study were fasted for 12 hours prior to surgical intervention, which resulted in loss of 
2.4±1.9kg of body weight from pre-fasting measurements. Although the difference in 
fasting weight loss is small, it is possible that it may have contributed to the variability in 
physiologic and metabolic response that was observed. Fixed pressure haemorrhage 
could be used as an alternative as it would allow the degree and duration of hypotension 
to be controlled (215). However the need for repeated blood withdrawal or volume 
administration to maintain target pressure is not reflective of the clinical situation and 
introduces potential confounders. Maintaining pressure with crystalloids may result in 
iatrogenic haemodilution (272) whilst administration of anti-coagulated blood may cause 
iatrogenic anti-coagulation (67).   
 
Epidemiological work in human patients has shown that ATC is most likely to develop if an 
ISS of 25 or greater is combined with a minimum base deficit of 6mmol/L (29). The model 
used in this thesis was designed to simulate an ISS of 25 based upon this work. As a 
result it may be worthwhile targeting haemorrhage to a variable predictive of ATC, rather 
than a target blood pressure or volume as these have not proven to predict the onset of 
coagulopathy. While a significant rise in base deficit was not evident in this thesis the 
severe trauma animals did demonstrate a significant rise in blood lactate levels, which 
have proven to be a sensitive predictor of mortality and need for resuscitation in clinical 
studies (249, 250).  Qualitative evaluation of data from this study and other published 
experimental models suggests that animals that develop a lactate value of 4mmol/L or 
more following trauma and haemorrhage were more likely to develop a clinically relevant 
coagulopathy (table 6) (29, 40, 65, 67). Therefore it may be more appropriate to target 
haemorrhage to a minimum blood lactate level of 4mmol/L, rather than a fixed volume 
based upon body weight or a fixed pressure. This may improve the reproducibility of the 
proposed model, whilst also accelerating the time point at which a clinically relevant 
coagulopathy becomes evident.   
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Table 6.  Lactate values and coagulation changes in published animal trauma and haemorrhage 
models. 
Authors Mean lactate values post 
trauma and 
haemorrhage 
Clinically 
relevant 
coagulopathy 
Coagulation findings 
van Zyl et al      1.88±0.37mmol/L at 1hr 
(Moderate) 
Borderline aPTT 34.75±2.50s (4hrs) 
INR ↑22.5±1.0% (4hrs) 
4.15±0.70mmol/L at 1hr 
(Severe) 
Yes aPTT 34.25±1.71s (2hrs) 
INR ↑22.5±6.0% (4hrs)  
EXTEM A10 40.75±8.42 (3hrs) 
Duan et al (67) 4.98±1.4mmol/L at 10min Yes INR ↑ 23±0.7% (40 min) 
Darlington et al 
(65) 
5.6±0.4mmol/L at 40min Yes PT 21.6±0.3s (1hr) 
Frith et al (29) 8.6±2.0mmol/L Yes PT 23.5±2.4s 
Chesebro et al 
(40) 
10.7±3.6mmol/L at 1hr Yes aPTT 35.3±3.1s (1hr) 
Mulier et al 
(202) 
2.0±1.3mmol/L at 45min No Increased CFT on TEG. 
 
5.2.2 Further investigation of proposed pathophysiological mechanisms 
This thesis evaluated changes in platelet function, markers of endothelial glycocalyx 
degradation, components of the protein C pathway and fibrinolytic function that 
accompanied the onset of coagulopathy in the severe trauma animals. As a result it 
encompassed aspects of all major hypothesised pathophysiological mechanisms (270).  
However as this thesis was primarily aimed at model development the examination of 
proposed pathophysiological mechanisms was purely observational in nature. Calculated 
correlation coefficients examined the relationships between coagulopathy and various 
biomarkers, further supporting hypothesised contributions of the endothelial glycocalyx 
and protein C pathway. However correlation does not equate to causation and further 
mechanistic studies are indicated to better elucidate the mechanisms underlying the 
development of ATC. 
 
The ability to evaluate isolated pathways within the coagulation system has been 
demonstrated in a murine model of ATC, in which the administration of activated protein C 
antibodies stopped the development of coagulopathy (40). However more detailed 
investigation in rodent models has been limited by animal size and established differences 
in coagulation function (58, 224). Refinement of the model used in this thesis may facilitate 
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mechanistic evaluation of ATC on a larger scale via the interference or manipulation of 
isolated pathways. The development of ovine antibodies to various aspects of the protein 
C pathway would facilitate a more detailed assessment of the contribution of various 
components of the pathway to ATC. Assessment of plasmin-antiplasmin complexes would 
better reflect the degree of fibrinolysis in the model (112), and manipulation of PAI-1 and 
tPA may improve understanding of the mechanism underlying fibrinolysis. A better 
understanding of the microcirculation and endothelial glycocalyx may be elucidated 
through the use of electron microscopy, organ microdialysis and sidestream dark field 
camera application (136, 273, 274). The role of endogenous heparinisation could also be 
better assessed via the use of anti-Xa assays (275). Immunohistochemistry (IHC) to 
investigate the tissue expression of biomarkers such as thrombomodulin in addition to 
measuring circulating levels will also contribute to improved understanding, particularly 
given the controversies regarding the action of sTM. This was considered in this thesis; 
however no commercially available ovine thrombomodulin antibodies suitable for IHC were 
able to be located. Cross reactivity with human (thrombomodulin/BDCA antibody, R&D 
systems), bovine (thrombomodulin antibody, Biorbyt) and caprine (thrombomodulin 
antibody, Enzo Life Sciences Inc) antibodies was assessed, with none found. 
Thrombomodulin IHC would therefore require the development of ovine specific antibodies 
which was beyond the scope of this thesis. 
 
The evaluation of additional pathophysiological theories is also indicated in future work.  
Coagulation dysfunction triggers a de novo systemic inflammatory response, which may 
contribute to the increased incidence of sepsis and multiorgan failure in trauma patients 
(50, 276). ATC has been associated with increased cytokine expression (most notably 
TNF- and IL-1) and complement activation via the release of mitochondrial damage-
associated molecular patterns (DAMPs) (276). Immune activation may therefore aggravate 
tissue damage and amplify haemostatic activation. In addition trauma patients have 
demonstrated an increase in platelet derived microparticles (PMPs) that were associated 
with increased blood product requirements and mortality (148, 149). These PMPs are 
thought to also have pro-inflammatory effects and may play an important role in linking 
coagulation and inflammation; however the precise contribution to ATC is still 
undetermined. Methodological evaluation of inflammatory markers and PMPs in a 
controlled fashion using an in vivo model may help elucidate the contribution of these 
additional factors to ATC.    
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5.2.3 Investigation of proposed therapeutic strategies.  
Haemostatic or ‘damage control’ resuscitation regimens form the current core therapeutic 
approach to patients with traumatic injury. It is perceived that these regimens restore 
circulating volume and reverse coagulopathy, resulting in improved patient outcomes (51, 
52, 81, 82). However a recent prospective study demonstrated worsening haemostatic 
function in trauma patients despite the use of haemostatic resuscitation,  suggesting 
factors other than correction of coagulopathy may contribute to the survival benefits 
associated with these regimens (80).   
 
The composition of haemostatic resuscitation varies between countries and institutions 
(84-86), reflecting a lack of understanding of the benefits and risks of individual blood 
components in trauma. There is some evidence to suggest that fresh frozen plasma (FFP) 
may have a protective and restorative effect on the endothelial glycocalyx (137, 178), a 
property that has not been described with fibrinogen concentrate or cryoprecipitate. This 
may make FFP an attractive option for inclusion in resuscitation regimens given the 
proposed contribution of the glycocalyx to ATC. However a systematic review evaluating 
the comparative clinical effectiveness of FFP and fibrinogen demonstrated no significant 
difference in outcomes (277). Refinement of the model proposed by this thesis would allow 
more detailed evaluation of the effects of FFP and other resuscitation components on the 
endothelial glycocalyx and haemostatic response. Differing resuscitation regimens could 
also be compared, which may better inform subsequent human studies.  
 
5.3 Concluding statement 
 
Pre-clinical animal research is a necessary adjunct for improving the understanding and 
management of ATC given the acknowledged limitations of human research in the 
emergency setting. Creating a clinically relevant model of ATC that facilitates translation of 
results to humans is difficult given the complexity of the condition and known limitations of 
animal research. This thesis describes the development of the first ovine model of trauma 
and haemorrhage to demonstrate coagulation changes consistent with current definitions 
of ATC. The degree of coagulopathy was closely correlated with the degree of shock as 
quantified by arterial lactate levels, further supporting the importance of tissue 
hypoperfusion in the development of ATC. Observational assessment of proposed 
pathophysiological mechanisms within the model demonstrated a strong correlation 
between coagulopathy and activation of the protein C pathway, which supports 
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suggestions that protein C activation may play a central role in the development of ATC.  
Coagulopathy was also strongly correlated with an increase in markers of endothelial 
glycocalyx shedding, providing further evidence that the endothelial glycocalyx may 
contribute to the development of coagulopathy in trauma. However there was no evidence 
of fibrinolysis and no significant changes in induced platelet aggregation testing to suggest 
that fibrinolysis or platelet dysfunction made a significant contribution to coagulopathy in 
this thesis. 
 
Clinical definitions of ATC were evident 2-4 hours following injury in this thesis and the 
severe trauma animals did demonstrate variability in the metabolic and haemostatic 
response to trauma. This indicates the need for ongoing refinement of the proposed model 
in order to improve reproducibility and clinical relevance. Refinement may facilitate 
mechanistic evaluation of proposed pathophysiological mechanisms, which may improve 
understanding of the condition and identify novel therapeutic targets.  Refining the 
proposed model would also provide a platform for the evaluation of targeted and novel 
haemostatic interventions in a whole biological system, which may reduce exposure to 
blood products and help improve outcomes for trauma patients. 
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CHAPTER 7: APPENDICES 
7.1  Repeat statistical analysis of selected variables. 
Variability in response was evident in the severe trauma animals.  Animal 3 developed a 
higher blood lactate level and INR, longer aPTT and lower EXTEM A10 value than the 
other animals in the group (appendix 7.1.1). The impact of this variability on overall results 
was assessed by repeat statistical analysis of selected variables with this animal removed 
(appendix 7.1.2). A statistically significant difference in these variables remained, however 
the time at which statistical significance was achieved differed in some cases. The time at 
which the clinical definition of ATC was achieved was also prolonged (most notably for 
EXTEM A10) however all 3 proposed definitions were still met. 
 
7.1.1 Individual responses of severe trauma group animals to selected variables. 
The figures below demonstrate the individual responses of animals in the severe trauma to 
selected variables.  Animal 3 demonstrated a greater rise in INR [A] and lactate [B] than 
the other animals in the group.  A greater prolongation of aPTT [C] and reduction in 
EXTEM A10 values [D] was also demonstrated by animal 3 compared to the other animals 
in the group. 
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Figure 8. Individual responses of animals in the severe trauma group to selected variables. 
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7.1.2 Repeat statistical analysis of selected variables 
Repeat statistical analysis of the selected variables presented above was undertaken to 
ascertain if a statistically significant difference in response remained without the inclusion 
of animal 3 (table 7). A statistically significant difference in all variables remained following 
the exclusion of animal 3 (severe (3)). The aPTT based definition of ATC was still met at 2 
hours post injury (34.00 ± 2.00s) and a statistically significant difference (p =0.006) 
remained from 30 minutes post injury. However EXTEM A10 did not drop below 40mm 
until 6 hours post injury (37.00 ± 10.15mm) following the removal of animal 3, with a 
statistically significant difference (p=0.072) not evident until 5 hours post injury. 
 
Table 7.Repeat statistical analysis of selected variables following removal of severe trauma animal 
3.  Values are expressed as mean ± SD 
Variable Baseline 30 min 1 hr 2 hr 3 hr 4 hr 5 hr 6 hr 
aPTT (s) 
Control 
Moderate 
Severe 
Severe (3) 
 
24.25±1.50 
23.50±2.88 
24.75±1.50 
24.33±1.53 
 
23.50±1.92 
28.00±2.44 
32.50±4.20
* 
32.00±5.00
* 
 
23.25±1.89 
30.75±4.50
x 
33.00±2.58
* 
33.33±3.01
* 
 
24.00±2.00 
32.00±4.97
x 
34.25±1.71
* 
34.00±2.00
* 
 
24.50±2.08 
32.75±2.22
x 
36.25±4.35
* 
35.00±4.36
* 
 
23.75±2.88 
34.75±2.50
x 
39.25±4.99
* 
37.00±2.65
* 
 
24.25±2.50 
35.00±2.16
x 
42.00±8.16
* 
38.00±2.00
* 
 
24.75±2.50 
34.50±2.88
x 
44.50±6.56
* 
41.33±2.08
* 
INR 
Control 
Moderate 
Severe 
Severe (3) 
 
1.43±0.06 
1.33±0.06 
1.33±0.10 
1.30±0.10 
 
1.43±0.06 
1.38±0.10 
1.35±0.06 
1.33±0.06 
 
1.43±0.06 
1.48±0.06 
1.38±0.10 
1.33±0.06 
 
1.43±0.06 
1.48±0.06 
1.43±0.06 
1.40±0.06 
 
1.45±0.06 
1.55±0.06 
1.48±0.10 
1.43±0.06 
 
1.45±0.06 
1.63±0.06 
1.60±0.20 
1.50±0.00 
 
1.45±0.06 
1.65±0.06
x 
1.73±0.32
* 
1.58±0.06
* 
 
1.45±0.06 
1.65±0.06
x 
1.80±0.28
* 
1.68±0.06
* 
EXTEM 
A10 (mm) 
Control 
Moderate 
Severe 
Severe (3) 
 
 
61.00±6.06 
64.50±4.20 
59.00±2.70 
57.67±7.09 
 
 
55.75±4.44 
54.75±2.22 
48.50±3.42 
49.67±3.05 
 
 
54.75±4.58 
53.50±2.08 
47.25±2.62 
48.00±2.65 
 
 
52.00±5.94 
53.50±1.00 
45.25±2.40 
46.33±3.22 
 
 
53.00±5.72 
52.25±1.50 
40.75±8.42
* 
44.67±3.79 
 
 
51.75±8.34 
49.50±2.38 
38.25±13.2
* 
44.67±3.79 
 
 
54.00±6.80 
50.25±2.50 
35.25±14.72
* 
42.33±4.93
* 
 
 
52.75±6.60 
49.00±2.16 
31.25±14.2
* 
37.00±10.15
* 
Lactate 
(mmol/L) 
Control 
Moderate 
Severe 
Severe (3) 
 
 
1.23±0.38 
1.58±0.56 
1.48±0.26 
1.40±0.27 
 
 
0.58±0.20 
1.80±0.72 
3.50±1.08 
3.07±0.81 
 
 
0.53±0.20 
1.88±0.74 
4.15±1.39
* 
3.50±0.60
* 
 
 
0.53±0.16 
1.80±0.80 
4.68±1.93
* 
3.73±0.50
* 
 
 
0.55±0.20 
1.63±0.48 
4.70±2.80
* 
3.37±1.03
* 
 
 
0.50±0.14 
1.75±0.91 
5.58±4.10
* 
3.53±0.49
* 
 
 
0.55±0.14 
1.80±1.02 
6.13±5.08
* 
3.60±0.69
* 
 
 
0.55±0.09 
1.90±0.82 
6.73±5.30
* 
4.40±3.12
* 
Severe (3) = results with animal 3 removed, aPTT = activated partial thromboplastin time, INR = international 
normalised ratio, EXTEM A10 = clot amplitude at 10 minutes, * = significant difference between control and 
severe trauma groups p<0.05.  x = significant difference between control and moderate trauma groups 
p<0.05 
 
The original statistical analysis also demonstrated a significant rise in INR from baseline at 
3 hours post injury in both the moderate (p=0.002) and severe (p=0008) trauma groups 
compared to the control group, with a 20% increase from baseline evident from 4 hours 
(figure 9 [A]).  Following removal of severe trauma animal 3 the statistically significant 
increase in INR at 3 hours post injury in the severe trauma group compared to the control 
group was maintained (p=0.02).  However the time at which the INR based definition of 
ATC was met was prolonged, with a 20% increased from baseline not evident until 5 hours 
post injury (figure 9 [B]). 
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Figure 9. INR changes in this thesis [A] An increase in INR was evident in the moderate trauma 
(p=0.002) and severe trauma (p=0.008) groups compared to the control group, with a 20% 
increase from baseline evident at 4 hours. [B] This increase was maintained in the severe trauma 
group following removal of animal 3 (p=0.02), however a 20% increase in baseline was not evident 
until 5 hours. 
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